<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28481241</article-id><article-id pub-id-type="pmc">5454908</article-id><article-id pub-id-type="doi">10.3390/ijms18050995</article-id><article-id pub-id-type="publisher-id">ijms-18-00995</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Capper</surname><given-names>David</given-names></name><xref ref-type="aff" rid="af1-ijms-18-00995">1</xref><xref rid="c1-ijms-18-00995" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>von Deimling</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="af2-ijms-18-00995">2</xref></contrib><contrib contrib-type="author"><name><surname>Brandes</surname><given-names>Alba A.</given-names></name><xref ref-type="aff" rid="af3-ijms-18-00995">3</xref></contrib><contrib contrib-type="author"><name><surname>Carpentier</surname><given-names>Antoine F.</given-names></name><xref ref-type="aff" rid="af4-ijms-18-00995">4</xref></contrib><contrib contrib-type="author"><name><surname>Kesari</surname><given-names>Santosh</given-names></name><xref ref-type="aff" rid="af5-ijms-18-00995">5</xref></contrib><contrib contrib-type="author"><name><surname>Sepulveda-Sanchez</surname><given-names>Juan M.</given-names></name><xref ref-type="aff" rid="af6-ijms-18-00995">6</xref></contrib><contrib contrib-type="author"><name><surname>Wheeler</surname><given-names>Helen R.</given-names></name><xref ref-type="aff" rid="af7-ijms-18-00995">7</xref></contrib><contrib contrib-type="author"><name><surname>Chinot</surname><given-names>Olivier</given-names></name><xref ref-type="aff" rid="af8-ijms-18-00995">8</xref></contrib><contrib contrib-type="author"><name><surname>Cher</surname><given-names>Lawrence</given-names></name><xref ref-type="aff" rid="af9-ijms-18-00995">9</xref></contrib><contrib contrib-type="author"><name><surname>Steinbach</surname><given-names>Joachim P.</given-names></name><xref ref-type="aff" rid="af10-ijms-18-00995">10</xref></contrib><contrib contrib-type="author"><name><surname>Specenier</surname><given-names>Pol</given-names></name><xref ref-type="aff" rid="af11-ijms-18-00995">11</xref></contrib><contrib contrib-type="author"><name><surname>Rodon</surname><given-names>Jordi</given-names></name><xref ref-type="aff" rid="af12-ijms-18-00995">12</xref></contrib><contrib contrib-type="author"><name><surname>Cleverly</surname><given-names>Ann</given-names></name><xref ref-type="aff" rid="af13-ijms-18-00995">13</xref></contrib><contrib contrib-type="author"><name><surname>Smith</surname><given-names>Claire</given-names></name><xref ref-type="aff" rid="af13-ijms-18-00995">13</xref></contrib><contrib contrib-type="author"><name><surname>Gueorguieva</surname><given-names>Ivelina</given-names></name><xref ref-type="aff" rid="af13-ijms-18-00995">13</xref></contrib><contrib contrib-type="author"><name><surname>Miles</surname><given-names>Colin</given-names></name><xref ref-type="aff" rid="af13-ijms-18-00995">13</xref></contrib><contrib contrib-type="author"><name><surname>Guba</surname><given-names>Susan C.</given-names></name><xref ref-type="aff" rid="af14-ijms-18-00995">14</xref></contrib><contrib contrib-type="author"><name><surname>Desaiah</surname><given-names>Durisala</given-names></name><xref ref-type="aff" rid="af14-ijms-18-00995">14</xref></contrib><contrib contrib-type="author"><name><surname>Estrem</surname><given-names>Shawn T.</given-names></name><xref ref-type="aff" rid="af14-ijms-18-00995">14</xref></contrib><contrib contrib-type="author"><name><surname>Lahn</surname><given-names>Michael M.</given-names></name><xref ref-type="aff" rid="af14-ijms-18-00995">14</xref></contrib><contrib contrib-type="author"><name><surname>Wick</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="af15-ijms-18-00995">15</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Srivastava</surname><given-names>Sanjay K.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-18-00995"><label>1</label>Department of Neuropathology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany</aff><aff id="af2-ijms-18-00995"><label>2</label>Department of Neuropathology, University Hospital Heidelberg and Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; <email>andreas.vondeimling@med.uni-heidelberg.de</email></aff><aff id="af3-ijms-18-00995"><label>3</label>Medical Oncology Department, Bellaria-Maggiore Hospitals, Azienda USL—IRCCS Institute of Neurological Sciences, 40139 Bologna, Italy; <email>a.brandes@ausl.bo.it</email></aff><aff id="af4-ijms-18-00995"><label>4</label>Assistance Publique-Hôpitaux de Paris (AP-HP) &amp; Paris 13 University, Hôpital Avicenne, Service de Neurologie, 93009 Bobigny, France; <email>antoine.carpentier@avc.aphp.fr</email></aff><aff id="af5-ijms-18-00995"><label>5</label>UC San Diego Health System, La Jolla, CA 92103, USA; <email>kesaris@jwci.org</email></aff><aff id="af6-ijms-18-00995"><label>6</label>Hospital Universitario 12 de Octubre, 28041 Madrid, Spain; <email>jmsepulveda.hdoc@salud.madrid.org</email></aff><aff id="af7-ijms-18-00995"><label>7</label>Department of Oncology, Royal North Shore Hospital, St. Leonards, NSW 2065, Australia; <email>hrwheeler@optusnet.com.au</email></aff><aff id="af8-ijms-18-00995"><label>8</label>CHU Hôpital De La Timone, Rue Saint Pierre, 13385 Marseille, France; <email>olivier.chinot@ap-hm.fr</email></aff><aff id="af9-ijms-18-00995"><label>9</label>Austin Hospital, Heidelberg, VIC 3084, Australia; <email>lmcher@mac.com</email></aff><aff id="af10-ijms-18-00995"><label>10</label>Dr. Senckenberg Institute of Neurooncology, University Hospital Frankfurt, 60590 Frankfurt, Germany; <email>Joachim.steinbach@med.uni-frankfurt.de</email></aff><aff id="af11-ijms-18-00995"><label>11</label>Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium; <email>pol.specenier@uza.be</email></aff><aff id="af12-ijms-18-00995"><label>12</label>Medical Oncology, Vall d’Hebron University Hospital, Calle Natzaret, 115-117, 08035 Barcelona, Spain; <email>jrodon@vhebron.net</email></aff><aff id="af13-ijms-18-00995"><label>13</label>Eli Lilly and Company, Erl Wood Manor, Windlesham GU20 6PH, UK; <email>cleverly_ann_louise@lilly.com</email> (A.C.); <email>csmith@lilly.com</email> (C.S.); <email>gueorguieva_ivelina@lilly.com</email> (I.G.); <email>miles_colin_p@lilly.com</email> (C.M.)</aff><aff id="af14-ijms-18-00995"><label>14</label>Eli Lilly and Company, Indianapolis, IN 46285, USA; <email>guba_susan_c@lilly.com</email> (S.C.G.); <email>desaiah_durisala@lilly.com</email> (D.D.); <email>estrem_shawn_t@lilly.com</email> (S.T.E.); <email>michalahn@aol.com</email> (M.M.L.)</aff><aff id="af15-ijms-18-00995"><label>15</label>Department of Neurology, University Hospital Heidelberg, 69120 Heidelberg, Germany; <email>wolfgang.wick@med.uni-heidelberg.de</email></aff><author-notes><corresp id="c1-ijms-18-00995"><label>*</label>Correspondence: <email>david.capper@charite.de</email>; Tel.: +49-30-450-536498</corresp></author-notes><pub-date pub-type="epub"><day>06</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2017</year></pub-date><volume>18</volume><issue>5</issue><elocation-id>995</elocation-id><history><date date-type="received"><day>14</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>25</day><month>4</month><year>2017</year></date></history><permissions><copyright-statement>© 2017 by the authors.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><offsets xml_i="9057" xml_f="9716" txt_i="11" txt_f="670">Galunisertib, a Transforming growth factor-βRI (TGF-βRI) kinase inhibitor, blocks TGF-β-mediated tumor growth in glioblastoma. In a three-arm study of galunisertib (300 mg/day) monotherapy (intermittent dosing; each cycle =14 days on/14 days off), lomustine monotherapy, and galunisertib plus lomustine therapy, baseline tumor tissue was evaluated to identify markers associated with tumor stage (e.g., histopathology, Ki67, glial fibrillary acidic protein) and TGF-β-related signaling (e.g., pSMAD2). Other pharmacodynamic assessments included chemokine, cytokine, and T cell subsets alterations. 158 patients were randomized to galunisertib plus lomustine (</offsets><italic><offsets xml_i="9724" xml_f="9725" txt_i="670" txt_f="671">n</offsets></italic><offsets xml_i="9734" xml_f="9756" txt_i="671" txt_f="693"> = 79), galunisertib (</offsets><italic><offsets xml_i="9764" xml_f="9765" txt_i="693" txt_f="694">n</offsets></italic><offsets xml_i="9774" xml_f="9804" txt_i="694" txt_f="724"> = 39) and placebo+lomustine (</offsets><italic><offsets xml_i="9812" xml_f="9813" txt_i="724" txt_f="725">n</offsets></italic><offsets xml_i="9822" xml_f="9951" txt_i="725" txt_f="854"> = 40). In 127 of these patients, tissue was adequate for central pathology review and biomarker work. Isocitrate dehydrogenase (</offsets><italic><offsets xml_i="9959" xml_f="9963" txt_i="854" txt_f="858">IDH1</offsets></italic><offsets xml_i="9972" xml_f="10025" txt_i="858" txt_f="911">) negative glioblastoma patients with baseline pSMAD2</offsets><sup><offsets xml_i="10030" xml_f="10031" txt_i="911" txt_f="912">+</offsets></sup><offsets xml_i="10037" xml_f="10156" txt_i="912" txt_f="1031"> in cytoplasm had median overall survival (OS) 9.5 months vs. 6.9 months for patients with no tumor pSMAD2 expression (</offsets><italic><offsets xml_i="10164" xml_f="10165" txt_i="1031" txt_f="1032">p</offsets></italic><offsets xml_i="10174" xml_f="10216" txt_i="1032" txt_f="1074"> = 0.4574). Eight patients were IDH1 R132H</offsets><sup><offsets xml_i="10221" xml_f="10222" txt_i="1074" txt_f="1075">+</offsets></sup><offsets xml_i="10228" xml_f="10326" txt_i="1075" txt_f="1173"> and had a median OS of 10.4 months compared to 6.9 months for patients with negative IDH1 R132H (</offsets><italic><offsets xml_i="10334" xml_f="10335" txt_i="1173" txt_f="1174">p</offsets></italic><offsets xml_i="10344" xml_f="10503" txt_i="1174" txt_f="1333"> = 0.5452). IDH1 status was associated with numerically higher plasma macrophage-derived chemokine (MDC/CCL22), higher whole blood FOXP3, and reduced tumor CD3</offsets><sup><offsets xml_i="10508" xml_f="10509" txt_i="1333" txt_f="1334">+</offsets></sup><offsets xml_i="10515" xml_f="10610" txt_i="1334" txt_f="1429"> T cell counts. Compared to the baseline, treatment with galunisertib monotherapy preserved CD4</offsets><sup><offsets xml_i="10615" xml_f="10616" txt_i="1429" txt_f="1430">+</offsets></sup><offsets xml_i="10622" xml_f="10799" txt_i="1430" txt_f="1607"> T cell counts, eosinophils, lymphocytes, and the CD4/CD8 ratio. The T-regulatory cell compartment was associated with better OS with MDC/CCL22 as a prominent prognostic marker.</offsets></p></abstract><kwd-group><kwd>galunisertib monohydrate (LY2157299)</kwd><kwd>TGF-β</kwd><kwd>pSMAD2</kwd><kwd>CDK4/CDK6</kwd><kwd>biomarkers</kwd></kwd-group></article-meta></front><body><sec id="sec1-ijms-18-00995"><title><offsets xml_i="11023" xml_f="11038" txt_i="1615" txt_f="1630">1. Introduction</offsets></title><p><offsets xml_i="11049" xml_f="11248" txt_i="1631" txt_f="1830">Glioblastoma is the most common brain cancer in adults, and, despite aggressive treatment with surgery and chemoradiation, the median survival remains approximately 15 months from initial diagnosis [</offsets><xref rid="B1-ijms-18-00995" ref-type="bibr"><offsets xml_i="11293" xml_f="11294" txt_i="1830" txt_f="1831">1</offsets></xref><offsets xml_i="11301" xml_f="11449" txt_i="1831" txt_f="1979">]. Glioblastoma is genetically and histopathologically diverse, which may require the development of inhibitors for specific subgroups of patients [</offsets><xref rid="B2-ijms-18-00995" ref-type="bibr"><offsets xml_i="11494" xml_f="11495" txt_i="1979" txt_f="1980">2</offsets></xref><offsets xml_i="11502" xml_f="11503" txt_i="1980" txt_f="1981">,</offsets><xref rid="B3-ijms-18-00995" ref-type="bibr"><offsets xml_i="11548" xml_f="11549" txt_i="1981" txt_f="1982">3</offsets></xref><offsets xml_i="11556" xml_f="11557" txt_i="1982" txt_f="1983">,</offsets><xref rid="B4-ijms-18-00995" ref-type="bibr"><offsets xml_i="11602" xml_f="11603" txt_i="1983" txt_f="1984">4</offsets></xref><offsets xml_i="11610" xml_f="11611" txt_i="1984" txt_f="1985">,</offsets><xref rid="B5-ijms-18-00995" ref-type="bibr"><offsets xml_i="11656" xml_f="11657" txt_i="1985" txt_f="1986">5</offsets></xref><offsets xml_i="11664" xml_f="11807" txt_i="1986" txt_f="2129">]. Transforming growth factor-β (TGF-β) signaling is a pathway that appears to be active in a specific subgroup of patients with glioblastoma [</offsets><xref rid="B6-ijms-18-00995" ref-type="bibr"><offsets xml_i="11852" xml_f="11853" txt_i="2129" txt_f="2130">6</offsets></xref><offsets xml_i="11860" xml_f="11861" txt_i="2130" txt_f="2131">,</offsets><xref rid="B7-ijms-18-00995" ref-type="bibr"><offsets xml_i="11906" xml_f="11907" txt_i="2131" txt_f="2132">7</offsets></xref><offsets xml_i="11914" xml_f="11915" txt_i="2132" txt_f="2133">,</offsets><xref rid="B8-ijms-18-00995" ref-type="bibr"><offsets xml_i="11960" xml_f="11961" txt_i="2133" txt_f="2134">8</offsets></xref><offsets xml_i="11968" xml_f="11969" txt_i="2134" txt_f="2135">,</offsets><xref rid="B9-ijms-18-00995" ref-type="bibr"><offsets xml_i="12014" xml_f="12015" txt_i="2135" txt_f="2136">9</offsets></xref><offsets xml_i="12022" xml_f="12023" txt_i="2136" txt_f="2137">,</offsets><xref rid="B10-ijms-18-00995" ref-type="bibr"><offsets xml_i="12069" xml_f="12071" txt_i="2137" txt_f="2139">10</offsets></xref><offsets xml_i="12078" xml_f="12079" txt_i="2139" txt_f="2140">,</offsets><xref rid="B11-ijms-18-00995" ref-type="bibr"><offsets xml_i="12125" xml_f="12127" txt_i="2140" txt_f="2142">11</offsets></xref><offsets xml_i="12134" xml_f="12274" txt_i="2142" txt_f="2282">]. For example, glioma cells that escape vascular endothelial growth factor (VEGF) inhibition continue to grow in a TGF-β-dependent manner [</offsets><xref rid="B6-ijms-18-00995" ref-type="bibr"><offsets xml_i="12319" xml_f="12320" txt_i="2282" txt_f="2283">6</offsets></xref><offsets xml_i="12327" xml_f="12466" txt_i="2283" txt_f="2422">]. Also, elevated TGF-β plasma ligand levels may be associated with increased numbers of T-regulatory cells in patients with glioblastoma [</offsets><xref rid="B7-ijms-18-00995" ref-type="bibr"><offsets xml_i="12511" xml_f="12512" txt_i="2422" txt_f="2423">7</offsets></xref><offsets xml_i="12519" xml_f="12685" txt_i="2423" txt_f="2589">]. The presence of both active TGF-β signaling and T-regulatory cells is hypothesized to shorten the prognosis of glioma patients, especially if TGF-β2 is expressed [</offsets><xref rid="B8-ijms-18-00995" ref-type="bibr"><offsets xml_i="12730" xml_f="12731" txt_i="2589" txt_f="2590">8</offsets></xref><offsets xml_i="12738" xml_f="12855" txt_i="2590" txt_f="2707">]. Upon engagement of the TGF-β receptor complex, the intracellular kinase of SMAD2 is activated by phosphorylation [</offsets><xref rid="B8-ijms-18-00995" ref-type="bibr"><offsets xml_i="12900" xml_f="12901" txt_i="2707" txt_f="2708">8</offsets></xref><offsets xml_i="12908" xml_f="13423" txt_i="2708" txt_f="3223">]. Hence, pSMAD2 expression in tumor tissue is commonly used to describe the degree of TGF-β signaling activation. pSMAD2 can be found either in a cytoplasmic or in a nuclear form, and nuclear pSMAD2 is considered the best read-out for a condition with activated TGF-β signaling. When using pSMAD2 as a marker for TGF-β signaling activation in glioblastoma patients, it appears that patients with high pSMAD2 expression have more aggressive and treatment-resistant tumors associated with low overall survival (OS) [</offsets><xref rid="B9-ijms-18-00995" ref-type="bibr"><offsets xml_i="13468" xml_f="13469" txt_i="3223" txt_f="3224">9</offsets></xref><offsets xml_i="13476" xml_f="13477" txt_i="3224" txt_f="3225">,</offsets><xref rid="B10-ijms-18-00995" ref-type="bibr"><offsets xml_i="13523" xml_f="13525" txt_i="3225" txt_f="3227">10</offsets></xref><offsets xml_i="13532" xml_f="13533" txt_i="3227" txt_f="3228">,</offsets><xref rid="B11-ijms-18-00995" ref-type="bibr"><offsets xml_i="13579" xml_f="13581" txt_i="3228" txt_f="3230">11</offsets></xref><offsets xml_i="13588" xml_f="13722" txt_i="3230" txt_f="3364">]. Thus, inhibitors of TGF-β signaling were postulated to improve OS by modifying tumor cell growth and restoring anti-tumor immunity.</offsets></p><p><offsets xml_i="13729" xml_f="13879" txt_i="3365" txt_f="3515">The small molecule inhibitor (SMI) galunisertib (LY2157299 monohydrate) showed anti-tumor effects in glioblastoma animal models and also in patients [</offsets><xref rid="B10-ijms-18-00995" ref-type="bibr"><offsets xml_i="13925" xml_f="13927" txt_i="3515" txt_f="3517">10</offsets></xref><offsets xml_i="13934" xml_f="13935" txt_i="3517" txt_f="3518">,</offsets><xref rid="B11-ijms-18-00995" ref-type="bibr"><offsets xml_i="13981" xml_f="13983" txt_i="3518" txt_f="3520">11</offsets></xref><offsets xml_i="13990" xml_f="13991" txt_i="3520" txt_f="3521">,</offsets><xref rid="B12-ijms-18-00995" ref-type="bibr"><offsets xml_i="14037" xml_f="14039" txt_i="3521" txt_f="3523">12</offsets></xref><offsets xml_i="14046" xml_f="14047" txt_i="3523" txt_f="3524">,</offsets><xref rid="B13-ijms-18-00995" ref-type="bibr"><offsets xml_i="14093" xml_f="14095" txt_i="3524" txt_f="3526">13</offsets></xref><offsets xml_i="14102" xml_f="14103" txt_i="3526" txt_f="3527">,</offsets><xref rid="B14-ijms-18-00995" ref-type="bibr"><offsets xml_i="14149" xml_f="14151" txt_i="3527" txt_f="3529">14</offsets></xref><offsets xml_i="14158" xml_f="14159" txt_i="3529" txt_f="3530">,</offsets><xref rid="B15-ijms-18-00995" ref-type="bibr"><offsets xml_i="14205" xml_f="14207" txt_i="3530" txt_f="3532">15</offsets></xref><offsets xml_i="14214" xml_f="14391" txt_i="3532" txt_f="3709">]. Galunisertib targets the serine-threonine kinase of the TGF-βRI and abrogates the phosphorylation of SMAD2, the initial intracellular protein of the TGF-β signaling pathway [</offsets><xref rid="B12-ijms-18-00995" ref-type="bibr"><offsets xml_i="14437" xml_f="14439" txt_i="3709" txt_f="3711">12</offsets></xref><offsets xml_i="14446" xml_f="14622" txt_i="3711" txt_f="3887">]. The overall activity of galunisertib was further supported by tumor responses in 16% of patients who progressed on their first- and second-line treatments for glioblastoma [</offsets><xref rid="B13-ijms-18-00995" ref-type="bibr"><offsets xml_i="14668" xml_f="14670" txt_i="3887" txt_f="3889">13</offsets></xref><offsets xml_i="14677" xml_f="14678" txt_i="3889" txt_f="3890">,</offsets><xref rid="B14-ijms-18-00995" ref-type="bibr"><offsets xml_i="14724" xml_f="14726" txt_i="3890" txt_f="3892">14</offsets></xref><offsets xml_i="14733" xml_f="14886" txt_i="3892" txt_f="4045">]. Preclinical studies also suggested that the combination of lomustine and galunisertib may have synergistic, or at least additive, anti-tumor effects [</offsets><xref rid="B15-ijms-18-00995" ref-type="bibr"><offsets xml_i="14932" xml_f="14934" txt_i="4045" txt_f="4047">15</offsets></xref><offsets xml_i="14941" xml_f="15328" txt_i="4047" txt_f="4434">]. Given the scientific hypothesis of blocking the TGF-β signaling pathway and based on the observations of preclinical and clinical anti-tumor activity in patients with glioblastoma, a Phase 2 study was initiated to evaluate the anti-tumor activity, safety, pharmacokinetics, and biomarker activity of galunisertib in combination with lomustine in patients with recurrent glioblastoma [</offsets><xref rid="B16-ijms-18-00995" ref-type="bibr"><offsets xml_i="15374" xml_f="15376" txt_i="4434" txt_f="4436">16</offsets></xref><offsets xml_i="15383" xml_f="15516" txt_i="4436" txt_f="4569">]. Unfortunately, the study did not show clinical benefit for galunisertib in combination with lomustine or galunisertib monotherapy.</offsets></p><p><offsets xml_i="15523" xml_f="15611" txt_i="4570" txt_f="4658">Here we report on the correlative biomarker studies conducted during the Phase 2 study [</offsets><xref rid="B16-ijms-18-00995" ref-type="bibr"><offsets xml_i="15657" xml_f="15659" txt_i="4658" txt_f="4660">16</offsets></xref><offsets xml_i="15666" xml_f="15856" txt_i="4660" txt_f="4850">]. Using a central neuropathology evaluation of all tumor tissue samples, it was possible to evaluate novel biomarkers related to TGF-β signaling in addition to a histopathology examination.</offsets></p></sec><sec id="sec2-ijms-18-00995"><title><offsets xml_i="15902" xml_f="15912" txt_i="4852" txt_f="4862">2. Results</offsets></title><sec id="sec2dot1-ijms-18-00995"><title><offsets xml_i="15960" xml_f="15999" txt_i="4863" txt_f="4902">2.1. Outcome from the Tissue Collection</offsets></title><p><offsets xml_i="16010" xml_f="16063" txt_i="4903" txt_f="4956">In this three-arm study, 158 patients were enrolled [</offsets><xref rid="B16-ijms-18-00995" ref-type="bibr"><offsets xml_i="16109" xml_f="16111" txt_i="4956" txt_f="4958">16</offsets></xref><offsets xml_i="16118" xml_f="16425" txt_i="4958" txt_f="5265">] of whom 142 patients had tumor tissue for central pathology review (90%), including 15 patients with unacceptable quality. In total, tumor tissue from 127 patients was considered to be of acceptable quality (127/158; 80%). Among the 127 tumor specimens, 118 were collected within two years of enrollment (</offsets><xref ref-type="app" rid="app1-ijms-18-00995"><offsets xml_i="16471" xml_f="16479" txt_i="5265" txt_f="5273">Table S1</offsets></xref><offsets xml_i="16486" xml_f="16488" txt_i="5273" txt_f="5275">).</offsets></p></sec><sec id="sec2dot2-ijms-18-00995"><title><offsets xml_i="16538" xml_f="16587" txt_i="5277" txt_f="5326">2.2. Description of Standard Pathology Evaluation</offsets></title><p><offsets xml_i="16598" xml_f="16769" txt_i="5327" txt_f="5498">Of the 127 patients with evaluable tissues, 120 patients had a confirmed grade IV diagnosis, including one case with a giant cell glioblastoma and three with gliosarcoma (</offsets><xref ref-type="table" rid="ijms-18-00995-t001"><offsets xml_i="16817" xml_f="16824" txt_i="5498" txt_f="5505">Table 1</offsets></xref><offsets xml_i="16831" xml_f="16833" txt_i="5505" txt_f="5507">).</offsets></p><p><offsets xml_i="16840" xml_f="16972" txt_i="5508" txt_f="5640">Based on the most recent diagnostic tumor specimens, the congruence between local neuropathologist and central review was over 90% (</offsets><xref ref-type="app" rid="app1-ijms-18-00995"><offsets xml_i="17018" xml_f="17026" txt_i="5640" txt_f="5648">Table S2</offsets></xref><offsets xml_i="17033" xml_f="17035" txt_i="5648" txt_f="5650">).</offsets></p><p><offsets xml_i="17042" xml_f="17085" txt_i="5651" txt_f="5694">Most patients had medium cellular density (</offsets><italic><offsets xml_i="17093" xml_f="17094" txt_i="5694" txt_f="5695">n</offsets></italic><offsets xml_i="17103" xml_f="17137" txt_i="5695" txt_f="5729"> = 100), endothelial hypertrophy (</offsets><italic><offsets xml_i="17145" xml_f="17146" txt_i="5729" txt_f="5730">n</offsets></italic><offsets xml_i="17155" xml_f="17203" txt_i="5730" txt_f="5778"> = 124), and necrosis without pseudopalisading (</offsets><italic><offsets xml_i="17211" xml_f="17212" txt_i="5778" txt_f="5779">n</offsets></italic><offsets xml_i="17221" xml_f="17229" txt_i="5779" txt_f="5787"> = 72) (</offsets><xref ref-type="table" rid="ijms-18-00995-t001"><offsets xml_i="17277" xml_f="17284" txt_i="5787" txt_f="5794">Table 1</offsets></xref><offsets xml_i="17291" xml_f="17374" txt_i="5794" txt_f="5877">). Approximately 20% of patients had presence of small cell astrocytoma-like foci (</offsets><italic><offsets xml_i="17382" xml_f="17383" txt_i="5877" txt_f="5878">n</offsets></italic><offsets xml_i="17392" xml_f="17415" txt_i="5878" txt_f="5901"> = 27) and microcysts (</offsets><italic><offsets xml_i="17423" xml_f="17424" txt_i="5901" txt_f="5902">n</offsets></italic><offsets xml_i="17433" xml_f="17492" txt_i="5902" txt_f="5961"> = 24). Most tumor cells had medium nuclear abnormalities (</offsets><italic><offsets xml_i="17500" xml_f="17501" txt_i="5961" txt_f="5962">n</offsets></italic><offsets xml_i="17510" xml_f="17535" txt_i="5962" txt_f="5987"> = 92) and 6–20 mitoses (</offsets><italic><offsets xml_i="17543" xml_f="17544" txt_i="5987" txt_f="5988">n</offsets></italic><offsets xml_i="17553" xml_f="18033" txt_i="5988" txt_f="6468"> = 66). Ki67 staining in 11–20% of cells was seen in 43 specimens, while the median H score for GFAP was 140. IDH1 R132H mutation was detected in eight specimens. No methylguanine methyltransferase (MGMT) assessment was conducted in this study. In all evaluable specimens, immunohistochemistry (IHC) detected pSMAD2 in the nuclei and in 22 cases (22/127; 17.3%) in the cytoplasm. CD3 IHC was assessed in two anatomical locations; perivascular and diffuse parenchymal infiltrates (</offsets><xref ref-type="table" rid="ijms-18-00995-t001"><offsets xml_i="18081" xml_f="18088" txt_i="6468" txt_f="6475">Table 1</offsets></xref><offsets xml_i="18095" xml_f="18114" txt_i="6475" txt_f="6494">). In 20 cases, CD3</offsets><sup><offsets xml_i="18119" xml_f="18120" txt_i="6494" txt_f="6495">+</offsets></sup><offsets xml_i="18126" xml_f="18373" txt_i="6495" txt_f="6742"> cell infiltrates were detected in the perivascular compartment with T cell infiltration, constituting ≥5% of the total parenchymal cell. Cellular density and the number of mitoses were correlated, and each was also correlated with Ki67 staining (</offsets><xref ref-type="app" rid="app1-ijms-18-00995"><offsets xml_i="18419" xml_f="18440" txt_i="6742" txt_f="6763">Supplemental Table S3</offsets></xref><offsets xml_i="18447" xml_f="18552" txt_i="6763" txt_f="6868">). In contrast, CD3 staining was not correlated with cellular density, mitoses, or Ki67 (data not shown).</offsets></p></sec><sec id="sec2dot3-ijms-18-00995"><title><offsets xml_i="18602" xml_f="18662" txt_i="6870" txt_f="6930">2.3. Association of Histopathology and Overall Survival (OS)</offsets></title><p><offsets xml_i="18673" xml_f="18944" txt_i="6931" txt_f="7202">We examined whether the histopathological findings from the original diagnostic tissue correlated with OS amongst patients with IDH1 negative glioblastoma. No statistically significant associations with OS were observed for any of the histological features summarized in </offsets><xref ref-type="table" rid="ijms-18-00995-t001"><offsets xml_i="18992" xml_f="18999" txt_i="7202" txt_f="7209">Table 1</offsets></xref><offsets xml_i="19006" xml_f="19008" txt_i="7209" txt_f="7211"> (</offsets><xref ref-type="fig" rid="ijms-18-00995-f001"><offsets xml_i="19054" xml_f="19062" txt_i="7211" txt_f="7219">Figure 1</offsets></xref><offsets xml_i="19069" xml_f="19071" txt_i="7219" txt_f="7221">).</offsets></p><p><offsets xml_i="19078" xml_f="19154" txt_i="7222" txt_f="7298">While not statistically significant, patients with increased parenchymal CD3</offsets><sup><offsets xml_i="19159" xml_f="19160" txt_i="7298" txt_f="7299">+</offsets></sup><offsets xml_i="19166" xml_f="19305" txt_i="7299" txt_f="7438"> lymphocytic infiltrate seemed to have shorter OS: ≤1% median OS 7.8 months; 2–4% median OS 6.7 months; ≥5% median OS 4.5 months (log rank </offsets><italic><offsets xml_i="19313" xml_f="19314" txt_i="7438" txt_f="7439">p</offsets></italic><offsets xml_i="19323" xml_f="19339" txt_i="7439" txt_f="7455">-value 0.7111) (</offsets><xref ref-type="fig" rid="ijms-18-00995-f002"><offsets xml_i="19385" xml_f="19393" txt_i="7455" txt_f="7463">Figure 2</offsets></xref><offsets xml_i="19400" xml_f="19405" txt_i="7463" txt_f="7468">A,B).</offsets></p><p><offsets xml_i="19412" xml_f="19446" txt_i="7469" txt_f="7503">When the data for the level of CD3</offsets><sup><offsets xml_i="19451" xml_f="19452" txt_i="7503" txt_f="7504">+</offsets></sup><offsets xml_i="19458" xml_f="19637" txt_i="7504" txt_f="7683"> infiltrates in both the vascular and ≥5% parenchymal compartments were combined, the median OS was 4.5 months compared to 7.2 months for all other patients with no or reduced CD3</offsets><sup><offsets xml_i="19642" xml_f="19643" txt_i="7683" txt_f="7684">+</offsets></sup><offsets xml_i="19649" xml_f="19679" txt_i="7684" txt_f="7714"> T cell infiltrates (log rank </offsets><italic><offsets xml_i="19687" xml_f="19688" txt_i="7714" txt_f="7715">p</offsets></italic><offsets xml_i="19697" xml_f="19735" txt_i="7715" txt_f="7753">-value = 0.1668) (data not shown). CD3</offsets><sup><offsets xml_i="19740" xml_f="19741" txt_i="7753" txt_f="7754">+</offsets></sup><offsets xml_i="19747" xml_f="19969" txt_i="7754" txt_f="7976"> cell infiltration in the tumor tissue was not significantly associated with peripheral lymphocyte counts, TGF-β1 plasma levels, macrophage-derived chemokine (MDC/CCL22) levels, or blood CD3% assessed at study enrollment (</offsets><xref ref-type="app" rid="app1-ijms-18-00995"><offsets xml_i="20015" xml_f="20024" txt_i="7976" txt_f="7985">Table S4a</offsets></xref><offsets xml_i="20031" xml_f="20033" txt_i="7985" txt_f="7987">).</offsets></p><p><offsets xml_i="20040" xml_f="20218" txt_i="7988" txt_f="8166">Patients with positive staining for cytoplasmic pSMAD2 had a median OS of 9.5 months compared to patients with no cytoplasmic pSMAD2, who had a median OS of 6.9 months (log rank </offsets><italic><offsets xml_i="20226" xml_f="20227" txt_i="8166" txt_f="8167">p</offsets></italic><offsets xml_i="20236" xml_f="20252" txt_i="8167" txt_f="8183">-value 0.4574) (</offsets><xref ref-type="fig" rid="ijms-18-00995-f002"><offsets xml_i="20298" xml_f="20306" txt_i="8183" txt_f="8191">Figure 2</offsets></xref><offsets xml_i="20313" xml_f="20318" txt_i="8191" txt_f="8196">C,D).</offsets></p><p><offsets xml_i="20325" xml_f="20434" txt_i="8197" txt_f="8306">No association was found between tissue pSMAD2 expression and TGF-β1 levels in plasma, FOXP3 in blood, or CD4</offsets><sup><offsets xml_i="20439" xml_f="20440" txt_i="8306" txt_f="8307">+</offsets></sup><offsets xml_i="20446" xml_f="20450" txt_i="8307" txt_f="8311">CD25</offsets><sup><offsets xml_i="20455" xml_f="20456" txt_i="8311" txt_f="8312">+</offsets></sup><offsets xml_i="20462" xml_f="20467" txt_i="8312" txt_f="8317">CD127</offsets><sup><offsets xml_i="20472" xml_f="20473" txt_i="8317" txt_f="8318">−</offsets></sup><offsets xml_i="20479" xml_f="20487" txt_i="8318" txt_f="8326">/LOFOXP3</offsets><sup><offsets xml_i="20492" xml_f="20493" txt_i="8326" txt_f="8327">+</offsets></sup><offsets xml_i="20499" xml_f="20554" txt_i="8327" txt_f="8382"> in plasma, collected at the time of study enrollment (</offsets><xref ref-type="app" rid="app1-ijms-18-00995"><offsets xml_i="20600" xml_f="20609" txt_i="8382" txt_f="8391">Table S4b</offsets></xref><offsets xml_i="20616" xml_f="20945" txt_i="8391" txt_f="8720">). In order to verify if temporal changes in parameters may be impacting the ability to determine associations between tissue and plasma markers, a sensitivity analysis including only the 36 patients with tissue collected within two months of study enrollment was conducted, and still no associations were found (data not shown).</offsets></p></sec><sec id="sec2dot4-ijms-18-00995"><title><offsets xml_i="20995" xml_f="21022" txt_i="8722" txt_f="8749">2.4. IDH1 Subgroup Analysis</offsets></title><p><offsets xml_i="21033" xml_f="21126" txt_i="8750" txt_f="8843">TGF-β-related signaling protein pSMAD2 was not increased in IDH1 mutation-positive patients (</offsets><xref ref-type="table" rid="ijms-18-00995-t002"><offsets xml_i="21174" xml_f="21181" txt_i="8843" txt_f="8850">Table 2</offsets></xref><offsets xml_i="21188" xml_f="21190" txt_i="8850" txt_f="8852">).</offsets></p><p><offsets xml_i="21197" xml_f="21207" txt_i="8853" txt_f="8863">Tissue CD3</offsets><sup><offsets xml_i="21212" xml_f="21213" txt_i="8863" txt_f="8864">+</offsets></sup><offsets xml_i="21219" xml_f="21345" txt_i="8864" txt_f="8990"> staining was greater in patients with IDH1 mutation-negative tumors compared to patients with IDH1 mutation-positive tumors (</offsets><italic><offsets xml_i="21353" xml_f="21354" txt_i="8990" txt_f="8991">p</offsets></italic><offsets xml_i="21363" xml_f="21443" txt_i="8991" txt_f="9071"> = 0.0260). Also, plasma levels of FOXP3 were higher in IDH1-positive patients (</offsets><italic><offsets xml_i="21451" xml_f="21452" txt_i="9071" txt_f="9072">p</offsets></italic><offsets xml_i="21461" xml_f="21473" txt_i="9072" txt_f="9084"> = 0.0394) (</offsets><xref ref-type="table" rid="ijms-18-00995-t002"><offsets xml_i="21521" xml_f="21528" txt_i="9084" txt_f="9091">Table 2</offsets></xref><offsets xml_i="21535" xml_f="21595" txt_i="9091" txt_f="9151">). Additionally, plasma levels of MDC/CCL22, TGF-β1, and CD4</offsets><sup><offsets xml_i="21600" xml_f="21601" txt_i="9151" txt_f="9152">+</offsets></sup><offsets xml_i="21607" xml_f="21733" txt_i="9152" txt_f="9278"> T cells were numerically higher in IDH1 positive patients compared to IDH1 negative patients (not statistically significant).</offsets></p></sec><sec id="sec2dot5-ijms-18-00995"><title><offsets xml_i="21783" xml_f="21813" txt_i="9280" txt_f="9310">2.5. Pharmacodynamic Responses</offsets></title><p><offsets xml_i="21824" xml_f="21922" txt_i="9311" txt_f="9409">Post-treatment changes relative to baseline values were assessed for the following parameters; CD4</offsets><sup><offsets xml_i="21927" xml_f="21928" txt_i="9409" txt_f="9410">+</offsets></sup><offsets xml_i="21934" xml_f="21939" txt_i="9410" txt_f="9415">, CD8</offsets><sup><offsets xml_i="21944" xml_f="21945" txt_i="9415" txt_f="9416">+</offsets></sup><offsets xml_i="21951" xml_f="21969" txt_i="9416" txt_f="9434">, the ratio of CD4</offsets><sup><offsets xml_i="21974" xml_f="21975" txt_i="9434" txt_f="9435">+</offsets></sup><offsets xml_i="21981" xml_f="21985" txt_i="9435" txt_f="9439">/CD8</offsets><sup><offsets xml_i="21990" xml_f="21991" txt_i="9439" txt_f="9440">+</offsets></sup><offsets xml_i="21997" xml_f="22002" txt_i="9440" txt_f="9445">, CD4</offsets><sup><offsets xml_i="22007" xml_f="22008" txt_i="9445" txt_f="9446">+</offsets></sup><offsets xml_i="22014" xml_f="22018" txt_i="9446" txt_f="9450">CD25</offsets><sup><offsets xml_i="22023" xml_f="22024" txt_i="9450" txt_f="9451">+</offsets></sup><offsets xml_i="22030" xml_f="22035" txt_i="9451" txt_f="9456">CD127</offsets><sup><offsets xml_i="22040" xml_f="22041" txt_i="9456" txt_f="9457">−</offsets></sup><offsets xml_i="22047" xml_f="22055" txt_i="9457" txt_f="9465">/LOFOXP3</offsets><sup><offsets xml_i="22060" xml_f="22061" txt_i="9465" txt_f="9466">+</offsets></sup><offsets xml_i="22067" xml_f="22291" txt_i="9466" txt_f="9690">, FOXP3 (%), and CD3 (%) by whole blood assay, eosinophils, lymphocytes, neutrophils, the neutrophil/lymphocyte ratio, monocytes, lactate dehydrogenase (LDH), S100β, C-reactive protein (CRP), MDC/CCL22, and TGF-β1 in plasma.</offsets></p><sec id="sec2dot5dot1-ijms-18-00995"><title><offsets xml_i="22339" xml_f="22400" txt_i="9691" txt_f="9752">2.5.1. Immune Monitoring and T Cell Subsets by Flow Cytometry</offsets></title><p><offsets xml_i="22411" xml_f="22433" txt_i="9753" txt_f="9775">At baseline, blood CD4</offsets><sup><offsets xml_i="22438" xml_f="22439" txt_i="9775" txt_f="9776">+</offsets></sup><offsets xml_i="22445" xml_f="22467" txt_i="9776" txt_f="9798"> T cell counts and CD4</offsets><sup><offsets xml_i="22472" xml_f="22473" txt_i="9798" txt_f="9799">+</offsets></sup><offsets xml_i="22479" xml_f="22483" txt_i="9799" txt_f="9803">CD25</offsets><sup><offsets xml_i="22488" xml_f="22489" txt_i="9803" txt_f="9804">+</offsets></sup><offsets xml_i="22495" xml_f="22500" txt_i="9804" txt_f="9809">CD127</offsets><sup><offsets xml_i="22505" xml_f="22506" txt_i="9809" txt_f="9810">−</offsets></sup><offsets xml_i="22512" xml_f="22520" txt_i="9810" txt_f="9818">/LOFOXP3</offsets><sup><offsets xml_i="22525" xml_f="22526" txt_i="9818" txt_f="9819">+</offsets></sup><offsets xml_i="22532" xml_f="22584" txt_i="9819" txt_f="9871"> T cell subsets were generally low. By contrast, CD8</offsets><sup><offsets xml_i="22589" xml_f="22590" txt_i="9871" txt_f="9872">+</offsets></sup><offsets xml_i="22596" xml_f="22631" txt_i="9872" txt_f="9907"> T cell subsets were mostly normal.</offsets></p><p><offsets xml_i="22638" xml_f="22699" txt_i="9908" txt_f="9969">While on treatment, there were significant differences in CD4</offsets><sup><offsets xml_i="22704" xml_f="22705" txt_i="9969" txt_f="9970">+</offsets></sup><offsets xml_i="22711" xml_f="22716" txt_i="9970" txt_f="9975">, CD4</offsets><sup><offsets xml_i="22721" xml_f="22722" txt_i="9975" txt_f="9976">+</offsets></sup><offsets xml_i="22728" xml_f="22732" txt_i="9976" txt_f="9980">/CD8</offsets><sup><offsets xml_i="22737" xml_f="22738" txt_i="9980" txt_f="9981">+</offsets></sup><offsets xml_i="22744" xml_f="22948" txt_i="9981" txt_f="10185"> ratio, eosinophils, and total lymphocyte counts. All these immune cells were reduced in patients treated in both lomustine-containing arms compared to the galunisertib monotherapy arm (overall treatment </offsets><italic><offsets xml_i="22956" xml_f="22957" txt_i="10185" txt_f="10186">p</offsets></italic><offsets xml_i="22966" xml_f="23175" txt_i="10186" txt_f="10392"> &lt; 0.05). Compared to the lomustine-containing treatments, eosinophils, neutrophils, total lymphocyte, and monocyte counts remained largely unchanged during monotherapy with galunisertib. Differences in CD4</offsets><sup><offsets xml_i="23180" xml_f="23181" txt_i="10392" txt_f="10393">+</offsets></sup><offsets xml_i="23187" xml_f="23209" txt_i="10393" txt_f="10415"> T cell counts and CD4</offsets><sup><offsets xml_i="23214" xml_f="23215" txt_i="10415" txt_f="10416">+</offsets></sup><offsets xml_i="23221" xml_f="23225" txt_i="10416" txt_f="10420">/CD8</offsets><sup><offsets xml_i="23230" xml_f="23231" txt_i="10420" txt_f="10421">+</offsets></sup><offsets xml_i="23237" xml_f="23373" txt_i="10421" txt_f="10557"> ratio were more apparent from cycle 4 onward, but this observation is limited because most patients discontinued treatment at cycle 2 (</offsets><xref ref-type="fig" rid="ijms-18-00995-f003"><offsets xml_i="23419" xml_f="23427" txt_i="10557" txt_f="10565">Figure 3</offsets></xref><offsets xml_i="23434" xml_f="23436" txt_i="10565" txt_f="10567">).</offsets></p><p><offsets xml_i="23443" xml_f="23740" txt_i="10568" txt_f="10862">For each of the five laboratory markers, patients with evaluable cycle 2 assessments were classified as having increased or decreased changes from baseline at cycle 2 (fold change ≥1 vs. fold change &lt;1). Increased values of each of the laboratory markers at cycle 2 were not prognostic for OS (</offsets><italic><offsets xml_i="23748" xml_f="23749" txt_i="10862" txt_f="10863">p</offsets></italic><offsets xml_i="23758" xml_f="23839" txt_i="10863" txt_f="10941"> &gt; 0.05) for any parameter in univariate analyses using Cox regression models.</offsets></p><p><offsets xml_i="23846" xml_f="24001" txt_i="10942" txt_f="11097">Other ratios such as CD8/CD3 (%) or CD8/total lymphocyte counts were explored, but there were no changes observed in these subpopulations (data not shown).</offsets></p></sec><sec id="sec2dot5dot2-ijms-18-00995"><title><offsets xml_i="24055" xml_f="24076" txt_i="11099" txt_f="11120">2.5.2. Plasma Markers</offsets></title><p><offsets xml_i="24087" xml_f="24642" txt_i="11121" txt_f="11676">TGF-β1 levels were not changed over time (data not shown). MDC/CCL22 levels were measured at baseline and at cycle 2. Mean reductions from baseline in MDC at cycle 2 were 11% (95% CI: −14% to 31%) for the galunisertib monotherapy arm, 27% (95% CI 13% to 39%) for the galunisertib plus lomustine arm, and 37% (95% CI 20% to 51%) for the placebo plus lomustine arm (data not shown). We also measured plasma levels of interleukin-2 (IL-2) using the same multi-analyte panel as for MDC/CCL22 levels, but the levels for IL-2 were undetectable (data not shown).</offsets></p><p><offsets xml_i="24649" xml_f="24892" txt_i="11677" txt_f="11920">LDH had a greater increase for the two lomustine arms relative to the galunisertib monotherapy arm from cycle 3 onward, noting that interpretation is limited given the small sample sizes remaining in the study at later visits (data not shown).</offsets></p><p><offsets xml_i="24899" xml_f="25034" txt_i="11921" txt_f="12056">None of the other parameters listed demonstrated significant differences in the changes from baseline among the treatment arms overall.</offsets></p></sec><sec id="sec2dot5dot3-ijms-18-00995"><title><offsets xml_i="25088" xml_f="25113" txt_i="12058" txt_f="12083">2.5.3. Genetic Evaluation</offsets></title><p><offsets xml_i="25124" xml_f="25562" txt_i="12084" txt_f="12522">Genetic variants (substitutions, short insertions and deletions, and copy number alterations) across 287 cancer related genes were identified for 70 tumor samples (~45% of the patients). The number of known/likely functional mutations detected per patient ranged from 1 to 12. The genes and types of mutations observed in this glioblastoma population matched the frequencies observed in previously characterized glioblastoma populations [</offsets><xref rid="B17-ijms-18-00995" ref-type="bibr"><offsets xml_i="25608" xml_f="25610" txt_i="12522" txt_f="12524">17</offsets></xref><offsets xml_i="25617" xml_f="25667" txt_i="12524" txt_f="12574">]. For example, epidermal growth factor receptor (</offsets><italic><offsets xml_i="25675" xml_f="25679" txt_i="12574" txt_f="12578">EGFR</offsets></italic><offsets xml_i="25688" xml_f="25746" txt_i="12578" txt_f="12636">) amplification/mutation was observed in 32 tumors (46%), </offsets><italic><offsets xml_i="25754" xml_f="25760" txt_i="12636" txt_f="12642">CDKN2A</offsets></italic><offsets xml_i="25769" xml_f="25832" txt_i="12642" txt_f="12705"> deletion detected in 39 (56%), and cyclin-dependent kinase-4 (</offsets><italic><offsets xml_i="25840" xml_f="25844" txt_i="12705" txt_f="12709">CDK4</offsets></italic><offsets xml_i="25853" xml_f="25997" txt_i="12709" txt_f="12853">) amplification in 10 (14%). However, in contrast with previous observations in a smaller galunisertib-treated glioblastoma patient population [</offsets><xref rid="B13-ijms-18-00995" ref-type="bibr"><offsets xml_i="26043" xml_f="26045" txt_i="12853" txt_f="12855">13</offsets></xref><offsets xml_i="26052" xml_f="26167" txt_i="12855" txt_f="12970">], genetic variants in these three genes were identified in both galunisertib responsive and non-responsive tumors.</offsets></p><p><offsets xml_i="26174" xml_f="26199" txt_i="12971" txt_f="12996">Previously, four of five </offsets><italic><offsets xml_i="26207" xml_f="26211" txt_i="12996" txt_f="13000">IDH1</offsets></italic><offsets xml_i="26220" xml_f="26276" txt_i="13000" txt_f="13056"> mutated tumors benefitted from galunisertib treatment [</offsets><xref rid="B13-ijms-18-00995" ref-type="bibr"><offsets xml_i="26322" xml_f="26324" txt_i="13056" txt_f="13058">13</offsets></xref><offsets xml_i="26331" xml_f="26442" txt_i="13058" txt_f="13169">]. Here, five of the sequenced tumors contained an IDH1 mutation. These five tumors were also determined to be </offsets><italic><offsets xml_i="26450" xml_f="26454" txt_i="13169" txt_f="13173">IDH1</offsets></italic><offsets xml_i="26463" xml_f="26526" txt_i="13173" txt_f="13236"> mutated by IDH1 R132H IHC assessment, and an additional three </offsets><italic><offsets xml_i="26534" xml_f="26538" txt_i="13236" txt_f="13240">IDH1</offsets></italic><offsets xml_i="26547" xml_f="26616" txt_i="13240" txt_f="13309"> mutated tumors were identified by IHC (sequence data not available).</offsets></p></sec></sec></sec><sec id="sec3-ijms-18-00995"><title><offsets xml_i="26674" xml_f="26687" txt_i="13313" txt_f="13326">3. Discussion</offsets></title><p><offsets xml_i="26698" xml_f="26776" txt_i="13327" txt_f="13405">Although we observed no treatment differences among the three treatment arms [</offsets><xref rid="B16-ijms-18-00995" ref-type="bibr"><offsets xml_i="26822" xml_f="26824" txt_i="13405" txt_f="13407">16</offsets></xref><offsets xml_i="26831" xml_f="27535" txt_i="13407" txt_f="14111">], we here present the integration of tissue- and blood-based biomarker examination in the same study. With the present approach, we assessed tumor tissue with histopathology and compared them to plasma markers. Plasma markers also allowed serial measurements of pharmacological changes in each treatment arm. The overall assessment, conducted centrally by neuropatholgists and central laboratories, including T cell subsets, is one of the most detailed assessments in glioblastoma patients treated with a TGF-β inhibitor. Despite the lack of treatment differences between the three arms, we here report also on some trends that may be useful to evaluate in future studies investigating TGF-β inhibition.</offsets></p><p><offsets xml_i="27542" xml_f="27736" txt_i="14112" txt_f="14306">Compared to the histopathology results provided by local histopathology laboratories, the results of the central review deviated in only seven patients from the local diagnosis of glioblastoma (</offsets><xref ref-type="app" rid="app1-ijms-18-00995"><offsets xml_i="27782" xml_f="27790" txt_i="14306" txt_f="14314">Table S2</offsets></xref><offsets xml_i="27797" xml_f="27937" txt_i="14314" txt_f="14454">). Overall, the standard histopathology review was consistent with a typical glioblastoma patient population with a low number of IDH1 R132H</offsets><sup><offsets xml_i="27942" xml_f="27943" txt_i="14454" txt_f="14455">+</offsets></sup><offsets xml_i="27949" xml_f="27967" txt_i="14455" txt_f="14473"> tumor specimens [</offsets><xref rid="B18-ijms-18-00995" ref-type="bibr"><offsets xml_i="28013" xml_f="28015" txt_i="14473" txt_f="14475">18</offsets></xref><offsets xml_i="28022" xml_f="28126" txt_i="14475" txt_f="14579">]. The anatomical features associated with Ki67, such as mitoses and cellular density, were correlated (</offsets><xref ref-type="app" rid="app1-ijms-18-00995"><offsets xml_i="28172" xml_f="28180" txt_i="14579" txt_f="14587">Table S3</offsets></xref><offsets xml_i="28187" xml_f="28343" txt_i="14587" txt_f="14743">). MGMT status was not part of the assessment but should be included for studies in which temozolomide-based therapy is part of the clinical investigation [</offsets><xref rid="B19-ijms-18-00995" ref-type="bibr"><offsets xml_i="28389" xml_f="28391" txt_i="14743" txt_f="14745">19</offsets></xref><offsets xml_i="28398" xml_f="28712" txt_i="14745" txt_f="15059">]. The reason for not performing MGMT testing was based on the limited amount of tumor tissue and the focus on TGF-β-associated signaling and immune markers. Today, advanced technology allows for MGMT testing with smaller tumor tissue specimens; hence, this test may be integrated in future TGF-β-directed studies.</offsets></p><p><offsets xml_i="28719" xml_f="28779" txt_i="15060" txt_f="15120">As previously reported for other studies with galunisertib [</offsets><xref rid="B13-ijms-18-00995" ref-type="bibr"><offsets xml_i="28825" xml_f="28827" txt_i="15120" txt_f="15122">13</offsets></xref><offsets xml_i="28834" xml_f="28835" txt_i="15122" txt_f="15123">,</offsets><xref rid="B16-ijms-18-00995" ref-type="bibr"><offsets xml_i="28881" xml_f="28883" txt_i="15123" txt_f="15125">16</offsets></xref><offsets xml_i="28890" xml_f="29002" txt_i="15125" txt_f="15237">], high baseline plasma levels of MDC/CCL22 were associated with better OS. In addition, we found that blood CD4</offsets><sup><offsets xml_i="29007" xml_f="29008" txt_i="15237" txt_f="15238">+</offsets></sup><offsets xml_i="29014" xml_f="29142" txt_i="15238" txt_f="15366"> T cell counts, T regulatory cells, and FOXP3 levels were also correlated with improved OS. In tumor tissue, the presence of CD3</offsets><sup><offsets xml_i="29147" xml_f="29148" txt_i="15366" txt_f="15367">+</offsets></sup><offsets xml_i="29154" xml_f="29400" txt_i="15367" txt_f="15613"> T cells in the parenchyma appeared to be numerically associated with reduced survival but were not statistically significant. Interestingly, there was no correlation between the CD3 levels as determined by an epigenetic test in blood and the CD3</offsets><sup><offsets xml_i="29405" xml_f="29406" txt_i="15613" txt_f="15614">+</offsets></sup><offsets xml_i="29412" xml_f="29501" txt_i="15614" txt_f="15703"> presence in tumor tissue as determined by IHC. The association of tumor-infiltrating CD3</offsets><sup><offsets xml_i="29506" xml_f="29507" txt_i="15703" txt_f="15704">+</offsets></sup><offsets xml_i="29513" xml_f="29585" txt_i="15704" txt_f="15776"> T cells with poor survival is different from other reports in which CD3</offsets><sup><offsets xml_i="29590" xml_f="29591" txt_i="15776" txt_f="15777">+</offsets></sup><offsets xml_i="29597" xml_f="29689" txt_i="15777" txt_f="15869"> tumor-infiltrating lymphocytes (TILs) are associated with improved OS, such as colorectal [</offsets><xref rid="B20-ijms-18-00995" ref-type="bibr"><offsets xml_i="29735" xml_f="29737" txt_i="15869" txt_f="15871">20</offsets></xref><offsets xml_i="29744" xml_f="29745" txt_i="15871" txt_f="15872">,</offsets><xref rid="B21-ijms-18-00995" ref-type="bibr"><offsets xml_i="29791" xml_f="29793" txt_i="15872" txt_f="15874">21</offsets></xref><offsets xml_i="29800" xml_f="29857" txt_i="15874" txt_f="15931">]. However, for glioblastoma, the association between CD3</offsets><sup><offsets xml_i="29862" xml_f="29863" txt_i="15931" txt_f="15932">+</offsets></sup><offsets xml_i="29869" xml_f="29933" txt_i="15932" txt_f="15996"> TILs and OS is less clear and mostly reported as inconclusive [</offsets><xref rid="B22-ijms-18-00995" ref-type="bibr"><offsets xml_i="29979" xml_f="29981" txt_i="15996" txt_f="15998">22</offsets></xref><offsets xml_i="29988" xml_f="29989" txt_i="15998" txt_f="15999">,</offsets><xref rid="B23-ijms-18-00995" ref-type="bibr"><offsets xml_i="30035" xml_f="30037" txt_i="15999" txt_f="16001">23</offsets></xref><offsets xml_i="30044" xml_f="30045" txt_i="16001" txt_f="16002">,</offsets><xref rid="B24-ijms-18-00995" ref-type="bibr"><offsets xml_i="30091" xml_f="30093" txt_i="16002" txt_f="16004">24</offsets></xref><offsets xml_i="30100" xml_f="30102" txt_i="16004" txt_f="16006">].</offsets></p><p><offsets xml_i="30109" xml_f="30296" txt_i="16007" txt_f="16194">We also attempted to stain for the presence of CCL22 in tumor tissue but were not able to establish a satisfactory staining protocol, which was based on previous work on lymphoma tissue [</offsets><xref rid="B25-ijms-18-00995" ref-type="bibr"><offsets xml_i="30342" xml_f="30344" txt_i="16194" txt_f="16196">25</offsets></xref><offsets xml_i="30351" xml_f="30525" txt_i="16196" txt_f="16370">]. Thus, it is not clear whether the high levels of CCL22 originate from the tumor or are produced systemically. This is important information as CCL22 may be produced by IDO</offsets><sup><offsets xml_i="30530" xml_f="30531" txt_i="16370" txt_f="16371">+</offsets></sup><offsets xml_i="30537" xml_f="30653" txt_i="16371" txt_f="16487"> dendritic cells in glioblastoma, which in turn may increase the generation of T regulatory cells in glioblastomas [</offsets><xref rid="B26-ijms-18-00995" ref-type="bibr"><offsets xml_i="30699" xml_f="30701" txt_i="16487" txt_f="16489">26</offsets></xref><offsets xml_i="30708" xml_f="30772" txt_i="16489" txt_f="16553">]. Interestingly, we also observed that patients with IDH1 R132H</offsets><sup><offsets xml_i="30777" xml_f="30778" txt_i="16553" txt_f="16554">+</offsets></sup><offsets xml_i="30784" xml_f="30929" txt_i="16554" txt_f="16699"> tumors had different immune baseline characteristics. These patients tended to have higher levels of markers associated with T regulatory cells.</offsets></p><p><offsets xml_i="30936" xml_f="31091" txt_i="16700" txt_f="16855">The TGF-β-related pathway in tumor tissue was assessed by staining for pSMAD2 as a marker of pathway activation. Similar to the First-in-Human Dose study [</offsets><xref rid="B13-ijms-18-00995" ref-type="bibr"><offsets xml_i="31137" xml_f="31139" txt_i="16855" txt_f="16857">13</offsets></xref><offsets xml_i="31146" xml_f="31401" txt_i="16857" txt_f="17112">], we observed that patients with higher baseline pSMAD2 levels in the tumor tissue had numerically better survival, but this was not statistically significant. Previous studies, however, found that high pSMAD2 staining was associated with poor survival [</offsets><xref rid="B9-ijms-18-00995" ref-type="bibr"><offsets xml_i="31446" xml_f="31447" txt_i="17112" txt_f="17113">9</offsets></xref><offsets xml_i="31454" xml_f="32134" txt_i="17113" txt_f="17793">], and perhaps these discrepancies may be explained by differences in staining protocols, assessment of cellular compartment (cytoplasmic versus nuclear staining), stage of tumor, and time interval since initial diagnosis. A limitation for this evaluation, however, represents the time interval of study participation and the pSMAD2 assessment on the original diagnostic tumor tissue. Generally, the time interval was about one year since the initial tumor was obtained and the patient started in this study. However, in this period, pSMAD2 expression may have changed, especially because patients completed chemo-radiation, which in turn may have affected the pathway activation.</offsets></p><p></p><p><offsets xml_i="32148" xml_f="32598" txt_i="17795" txt_f="18245">In accordance with previous reports, there was a trend toward positive correlation between IDH1 and OS. This trend was not statistically significant, possibly due to the small sample of IDH1-positive tumors. Gene mutations were also assessed in a subgroup of patients from which tumor material was left from the original investigation. In this subgroup of patients, we observed concordance (5/5) of the IDH1 R132H staining and DNA sequencing methods.</offsets></p><p><offsets xml_i="32605" xml_f="32849" txt_i="18246" txt_f="18490">Across all treatment arms, plasma levels of TGF-β1 were reduced with no difference among the treatments (data not shown). In other studies, reductions of plasma TGF-β1 levels were associated with either the removal of tumor mass after surgery [</offsets><xref rid="B27-ijms-18-00995" ref-type="bibr"><offsets xml_i="32895" xml_f="32897" txt_i="18490" txt_f="18492">27</offsets></xref><offsets xml_i="32904" xml_f="32939" txt_i="18492" txt_f="18527">] or responses after chemotherapy [</offsets><xref rid="B28-ijms-18-00995" ref-type="bibr"><offsets xml_i="32985" xml_f="32987" txt_i="18527" txt_f="18529">28</offsets></xref><offsets xml_i="32994" xml_f="32996" txt_i="18529" txt_f="18531">].</offsets></p><p><offsets xml_i="33003" xml_f="33327" txt_i="18532" txt_f="18856">However, there were some trends that are worth mentioning so they can be prospectively tested in future trials. First, lomustine treatments (with and without galunisertib) appeared to affect the lymphocyte counts. Second, patients who received only galunisertib seemed to conserve their lymphocyte counts and their subsets (</offsets><xref ref-type="fig" rid="ijms-18-00995-f003"><offsets xml_i="33373" xml_f="33381" txt_i="18856" txt_f="18864">Figure 3</offsets></xref><offsets xml_i="33388" xml_f="33523" txt_i="18864" txt_f="18999">). Among these patients there was a small subgroup that benefited from longer treatment with galunisertib and showed an increase in CD4</offsets><sup><offsets xml_i="33528" xml_f="33529" txt_i="18999" txt_f="19000">+</offsets></sup><offsets xml_i="33535" xml_f="33677" txt_i="19000" txt_f="19142"> T cell and lymphocyte counts. In contrast to the galunisertib monotherapy, for patients on the other two treatments containing lomustine, CD4</offsets><sup><offsets xml_i="33682" xml_f="33683" txt_i="19142" txt_f="19143">+</offsets></sup><offsets xml_i="33689" xml_f="34022" txt_i="19143" txt_f="19476"> T cell and lymphocyte counts seemed to decrease over time. Since the CD4/CD8 ratio did not change and lymphocytes increased overall, one should evaluate other lymphocyte subsets in future studies in galunisertib-treated patients. Third, patients who maintained their baseline levels of lymphocyte counts showed no increases of LDH (</offsets><xref ref-type="fig" rid="ijms-18-00995-f003"><offsets xml_i="34068" xml_f="34076" txt_i="19476" txt_f="19484">Figure 3</offsets></xref><offsets xml_i="34083" xml_f="34085" txt_i="19484" txt_f="19486">).</offsets></p><p><offsets xml_i="34092" xml_f="34256" txt_i="19487" txt_f="19651">In conclusion, our data support earlier studies, indicating that glioblastoma patients with conditions supporting T regulator cells have an improved survival rate [</offsets><xref rid="B29-ijms-18-00995" ref-type="bibr"><offsets xml_i="34302" xml_f="34304" txt_i="19651" txt_f="19653">29</offsets></xref><offsets xml_i="34311" xml_f="34571" txt_i="19653" txt_f="19913">]. The pre-existing conditions that may pre-dispose patients to develop glioblastoma may be similar to patients with increased peripheral immune tolerance and subsequent higher incidences of lung, colorectal, and estrogen receptor (ER)-negative breast cancer [</offsets><xref rid="B30-ijms-18-00995" ref-type="bibr"><offsets xml_i="34617" xml_f="34619" txt_i="19913" txt_f="19915">30</offsets></xref><offsets xml_i="34626" xml_f="34628" txt_i="19915" txt_f="19917">].</offsets></p></sec><sec id="sec4-ijms-18-00995"><title><offsets xml_i="34674" xml_f="34698" txt_i="19919" txt_f="19943">4. Materials and Methods</offsets></title><sec id="sec4dot1-ijms-18-00995" sec-type="subjects"><title><offsets xml_i="34766" xml_f="34779" txt_i="19944" txt_f="19957">4.1. Patients</offsets></title><p><offsets xml_i="34790" xml_f="35023" txt_i="19958" txt_f="20191">Adult male and female patients ≥18 years of age were eligible for enrollment in the study if they had been diagnosed with recurrent intracranial glioblastoma (World Health Organization Grade IV) confirmed by histological evaluation [</offsets><xref rid="B3-ijms-18-00995" ref-type="bibr"><offsets xml_i="35068" xml_f="35069" txt_i="20191" txt_f="20192">3</offsets></xref><offsets xml_i="35076" xml_f="35349" txt_i="20192" txt_f="20465">]. All patients had to have ≤1 on the Eastern Cooperative Oncology Group (ECOG) performance status scale. Patients were required to have evidence of tumor progression as determined by Response Assessment in Neuro Oncology (RANO) criteria following standard chemoradiation [</offsets><xref rid="B1-ijms-18-00995" ref-type="bibr"><offsets xml_i="35394" xml_f="35395" txt_i="20465" txt_f="20466">1</offsets></xref><offsets xml_i="35402" xml_f="35854" txt_i="20466" txt_f="20918">]. The study was conducted according to the principles of good clinical practice, applicable laws and regulations, and the Declaration of Helsinki. Each institution’s review board approved the study, and all patients signed an informed consent document before study participation. Informed consent was obtained from all individual participants included in the parent study from which the tissue and blood/plasma samples were obtained for this analysis.</offsets></p></sec><sec id="sec4dot2-ijms-18-00995"><title><offsets xml_i="35904" xml_f="35921" txt_i="20920" txt_f="20937">4.2. Study Design</offsets></title><p><offsets xml_i="35932" xml_f="36304" txt_i="20938" txt_f="21310">This was a three-arm, randomized, multinational, Phase 2 study of galunisertib monotherapy or galunisertib plus lomustine compared to lomustine plus placebo in patients with relapsed or progressed glioblastoma (Clinical Trial Registration: NCT01582269, 19 April 2012, ClinicalTrials.gov). Eligible patients were randomized in a 1:2:1 manner to these three treatment arms [</offsets><xref rid="B16-ijms-18-00995" ref-type="bibr"><offsets xml_i="36350" xml_f="36352" txt_i="21310" txt_f="21312">16</offsets></xref><offsets xml_i="36359" xml_f="36533" txt_i="21312" txt_f="21486">]. As previously described, anti-tumor activity was primarily based on assessing OS, and the secondary endpoints included overall response rate (ORR) based on RANO criteria [</offsets><xref rid="B16-ijms-18-00995" ref-type="bibr"><offsets xml_i="36579" xml_f="36581" txt_i="21486" txt_f="21488">16</offsets></xref><offsets xml_i="36588" xml_f="36590" txt_i="21488" txt_f="21490">].</offsets></p><sec id="sec4dot2dot1-ijms-18-00995"><title><offsets xml_i="36638" xml_f="36694" txt_i="21491" txt_f="21547">4.2.1. Central Pathology Review and Immunohistochemistry</offsets></title><p><offsets xml_i="36705" xml_f="37218" txt_i="21548" txt_f="22061">Formalin-fixed paraffin-embedded tumor specimens from the original diagnostic tissue were obtained and 5-μm sections were prepared. In cases in which a patient had more than one tumor tissue sample, the most recent diagnostic specimen was used for the central pathology review. The neuropathologist was blinded to treatments and their outcome and performed the subsequent examinations in a blinded fashion. All data were entered in a standardized fashion into a database and later combined with the clinical data.</offsets></p><p><offsets xml_i="37225" xml_f="37465" txt_i="22062" txt_f="22298">Hematoxylin and Eosin (H&amp;E) staining was performed to assess the general anatomical phenotype using characteristics such as differentiation, cellular density, vessel structure, tumor necrosis, nuclear abnormalities, and mitotic scoring.</offsets></p><p><offsets xml_i="37472" xml_f="37696" txt_i="22299" txt_f="22523">Additional staining was performed to assess the expression of glial fibrillary acidic protein (GFAP), Ki67, isocitrate dehydrogenase 1 (IDH1), R132H, pSMAD2, and CD3. Furthermore, tumor specimens were stained for MDC/CCL22 [</offsets><xref rid="B25-ijms-18-00995" ref-type="bibr"><offsets xml_i="37742" xml_f="37744" txt_i="22523" txt_f="22525">25</offsets></xref><offsets xml_i="37751" xml_f="37923" txt_i="22525" txt_f="22697">]. The process of evaluation was based on the standard IHC staining developed at the neuropathology laboratory at the University Clinic of Heidelberg, Heidelberg, Germany [</offsets><xref rid="B18-ijms-18-00995" ref-type="bibr"><offsets xml_i="37969" xml_f="37971" txt_i="22697" txt_f="22699">18</offsets></xref><offsets xml_i="37978" xml_f="37980" txt_i="22699" txt_f="22701">].</offsets></p></sec><sec id="sec4dot2dot2-ijms-18-00995"><title><offsets xml_i="38034" xml_f="38094" txt_i="22703" txt_f="22763">4.2.2. Central Laboratory Evaluation for Blood Based Markers</offsets></title><p><offsets xml_i="38105" xml_f="38225" txt_i="22764" txt_f="22884">Blood laboratory parameters included blood CD3 (%) (normal range: 17% to 36%), FOXP3 (%) (normal range: 1% to 3.6%), CD4</offsets><sup><offsets xml_i="38230" xml_f="38231" txt_i="22884" txt_f="22885">+</offsets></sup><offsets xml_i="38237" xml_f="38279" txt_i="22885" txt_f="22927"> (normal range: 441 to 2156 cells/μL), CD8</offsets><sup><offsets xml_i="38284" xml_f="38285" txt_i="22927" txt_f="22928">+</offsets></sup><offsets xml_i="38291" xml_f="38332" txt_i="22928" txt_f="22969">(normal range: 125 to 1312 cells/μL), CD4</offsets><sup><offsets xml_i="38337" xml_f="38338" txt_i="22969" txt_f="22970">+</offsets></sup><offsets xml_i="38344" xml_f="38348" txt_i="22970" txt_f="22974">CD25</offsets><sup><offsets xml_i="38353" xml_f="38354" txt_i="22974" txt_f="22975">+</offsets></sup><offsets xml_i="38360" xml_f="38365" txt_i="22975" txt_f="22980">CD127</offsets><sup><offsets xml_i="38370" xml_f="38371" txt_i="22980" txt_f="22981">−</offsets></sup><offsets xml_i="38377" xml_f="38385" txt_i="22981" txt_f="22989">/LOFOXP3</offsets><sup><offsets xml_i="38390" xml_f="38391" txt_i="22989" txt_f="22990">+</offsets></sup><offsets xml_i="38397" xml_f="38968" txt_i="22990" txt_f="23561"> (normal range estimated to be: approximately 18 to 86 cells/μL), neutrophils (normal range: 2.03 to 8.36 GI/L), lymphocytes (normal range: 1.02 to 3.36 GI/L), monocytes (normal range: 0.16 to 0.91 GI/L), eosinophils (normal range: 0 to 0.56 GI/L), plasma macrophage-derived chemokine/chemokine (c–c motif) ligand-22 (MDC/CCL22) (normal range: 181 to 571 pg/mL), plasma TGF-β1 (normal range: 741 to 3472 pg/mL), serum S100β (normal range: 0 to 96 ng/L), serum LDH (normal range: 80 to 250 U/L), and serum C-reactive protein (high sensitivity) (normal range: 0 to 3 mg/L).</offsets></p><p><offsets xml_i="38975" xml_f="39350" txt_i="23562" txt_f="23933">Plasma samples from patients were analyzed for TGF-β1 levels by enzyme‑linked immunosorbent assay (ELISA) (R&amp;D Systems, DB100B, Minneapolis, MN, USA). MDC/CCL22 levels were determined at baseline using the multi-analyte immunoassay panel (MAIP) developed by Myriad/RBM (Austin, TX, USA). Whole blood samples were used to determine the levels of T cell subsets such as CD4</offsets><sup><offsets xml_i="39355" xml_f="39356" txt_i="23933" txt_f="23934">+</offsets></sup><offsets xml_i="39362" xml_f="39370" txt_i="23934" txt_f="23942"> and CD8</offsets><sup><offsets xml_i="39375" xml_f="39376" txt_i="23942" txt_f="23943">+</offsets></sup><offsets xml_i="39382" xml_f="39390" txt_i="23943" txt_f="23951"> and CD4</offsets><sup><offsets xml_i="39395" xml_f="39396" txt_i="23951" txt_f="23952">+</offsets></sup><offsets xml_i="39402" xml_f="39406" txt_i="23952" txt_f="23956">CD25</offsets><sup><offsets xml_i="39411" xml_f="39412" txt_i="23956" txt_f="23957">+</offsets></sup><offsets xml_i="39418" xml_f="39423" txt_i="23957" txt_f="23962">CD127</offsets><sup><offsets xml_i="39428" xml_f="39429" txt_i="23962" txt_f="23963">−</offsets></sup><offsets xml_i="39435" xml_f="39443" txt_i="23963" txt_f="23971">/LOFOXP3</offsets><sup><offsets xml_i="39448" xml_f="39449" txt_i="23971" txt_f="23972">+</offsets></sup><offsets xml_i="39455" xml_f="39623" txt_i="23972" txt_f="24140"> by standard flow cytometry. In addition, the percentages of FOXP3 and CD3 were determined in whole blood using an epigenetic T cell assay (Epiontis, Berlin, Germany) [</offsets><xref rid="B31-ijms-18-00995" ref-type="bibr"><offsets xml_i="39669" xml_f="39671" txt_i="24140" txt_f="24142">31</offsets></xref><offsets xml_i="39678" xml_f="39680" txt_i="24142" txt_f="24144">].</offsets></p></sec><sec id="sec4dot2dot3-ijms-18-00995"><title><offsets xml_i="39734" xml_f="39759" txt_i="24146" txt_f="24171">4.2.3. Genetic Evaluation</offsets></title><p><offsets xml_i="39770" xml_f="39973" txt_i="24172" txt_f="24375">For 70 patients, there was sufficient tumor tissue from which DNA for mutation assessments was extracted and sequenced for 287 frequently mutated cancer genes by Foundation Medicine, Cambridge, MA, USA [</offsets><xref rid="B32-ijms-18-00995" ref-type="bibr"><offsets xml_i="40019" xml_f="40021" txt_i="24375" txt_f="24377">32</offsets></xref><offsets xml_i="40028" xml_f="40163" txt_i="24377" txt_f="24512">]. The 70 patients were distributed across the three arms of the study and were representative of the intent-to-treat (ITT) population.</offsets></p></sec></sec><sec id="sec4dot3-ijms-18-00995"><title><offsets xml_i="40219" xml_f="40244" txt_i="24515" txt_f="24540">4.3. Statistical Analyses</offsets></title><p><offsets xml_i="40255" xml_f="40432" txt_i="24541" txt_f="24718">Potential prognostic histopathology factors, as measured at baseline, were evaluated for their impact on OS, utilizing univariate Cox models from which any characteristics with </offsets><italic><offsets xml_i="40440" xml_f="40441" txt_i="24718" txt_f="24719">p</offsets></italic><offsets xml_i="40450" xml_f="40557" txt_i="24719" txt_f="24826"> ≤ 0.05 were to be selected for subsequent multivariate analysis. In addition, the OS for patients with CD3</offsets><sup><offsets xml_i="40562" xml_f="40563" txt_i="24826" txt_f="24827">+</offsets></sup><offsets xml_i="40569" xml_f="40774" txt_i="24827" txt_f="25032"> lymphocytic infiltration and OS for patients with positive staining for pSMAD2 were summarized descriptively using the Kaplan–Meier method. Associations between tissue and plasma markers were summarized; </offsets><italic><offsets xml_i="40782" xml_f="40783" txt_i="25032" txt_f="25033">p</offsets></italic><offsets xml_i="40792" xml_f="41060" txt_i="25033" txt_f="25301">-values for comparisons were calculated by analysis of variance using log transformed data for continuous measures and Fisher’s exact test for categorical measures. Post-treatment changes relative to baseline values were evaluated for laboratory markers. Data were log</offsets><sub><offsets xml_i="41065" xml_f="41066" txt_i="25301" txt_f="25302">e</offsets></sub><offsets xml_i="41072" xml_f="41435" txt_i="25302" txt_f="25665">-transformed prior to analysis, and the log ratio to baseline was analyzed by mixed effect model repeated measures (MMRM), adjusting for treatment, visit, treatment-by-visit interaction, and baseline-by-visit interaction. Repeated assessments were accounted for using an unstructured variance covariance matrix. For parameters with an overall treatment effect of </offsets><italic><offsets xml_i="41443" xml_f="41444" txt_i="25665" txt_f="25666">p</offsets></italic><offsets xml_i="41453" xml_f="41538" txt_i="25666" txt_f="25751"> ≤ 0.05, the geometric mean ratio to baseline was presented for each treatment group.</offsets></p></sec></sec></body><back><ack><title>Acknowledgments</title><p>This study was sponsored by Eli Lilly and Company, Indianapolis, IN, USA. The authors thank the patients for their willingness to participate in this study. Furthermore, we thank all site staff and investigators at the institutions, the trial personnel at Eli Lilly and Company, and Quintiles.</p></ack><app-group><app id="app1-ijms-18-00995"><title>Supplementary Materials</title><p>Supplementary materials can be found at <uri xlink:href="www.mdpi.com/1422-0067/18/5/995/s1">www.mdpi.com/1422-0067/18/5/995/s1</uri>.</p><supplementary-material content-type="local-data" id="ijms-18-00995-s001"><media xlink:href="ijms-18-00995-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>David Capper and Andreas von Deimling designed the format and evaluation for all pathological examinations; Alba A. Brandes, Antoine F. Carpentier, Santosh Kesari, Juan M. Sepulveda-Sanchez, Helen R. Wheeler, Olivier Chinot, Lawrence Cher, Joachim P. Steinbach, Pol Specenier, Jordi Rodon, and Wolfgang Wick contributed to the clinical study design and oversaw the safety and efficacy assessment during the clinical trials conduct; Ann Cleverly and Claire Smith conducted all statistical evaluations and interpretations; Ivelina Gueorguieva, Colin Miles, Susan C. Guba, and Michael M. Lahn designed, monitored, and were responsible for medical oversight of the study; Shawn T. Estrem was responsible for all biomarker evaluations; and Durisala Desaiah was involved in data review and manuscript writing.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Lawrence Cher, Olivier Chinot, Santosh Kesari, Jordi Rodon, Juan M. Sepulveda-Sanchez, Pol Specenier, and Helen R. Wheeler have no financial disclosures. David Capper and Andreas von Deimling report income from a patent held by the German cancer research center on an Antibody to detect R132H mutant IDH1 in fixed glioma samples, licensed to DIANOVA, Hamburg, Germany. Alba A. Brandes received traveling grants for ASCO, SNO, and ESMO meetings from Eli Lilly and Company, Roche, and Pfizer. Wolfgang Wick has received research grants from Apogenix, Boehringer Ingelheim, Eli Lilly and Company, Immatics, MSD, and Roche, as well as honoraria for lectures or advisory board participation from MSD and Roche. He is or has been the coordinating investigator for sponsored clinical trials evaluating APG101 (Apogenix), bevacizumab (Roche), galunisertib (Eli Lilly and Company), temozolomide (MSD), and temsirolimus (Pfizer). Joachim P. Steinbach has received a grant from Merck as well as honoraria for lectures, travel, or advisory board participation from Roche, Medam and Mundipharma. Antoine F. Carpentier served as a consultant for Roche. Ivelina Gueorguieva, Durisala Desaiah, Susan C. Guba, Ann Cleverly, Claire Smith, and Colin Miles are employees of Eli Lilly and Company, Indianapolis, IN, USA and may hold company stock. Michael M. Lahn is a former employee of Eli Lilly and Company and holds company stock.</p></notes><ref-list><title>References</title><ref id="B1-ijms-18-00995"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stupp</surname><given-names>R.</given-names></name><name><surname>Mason</surname><given-names>W.P.</given-names></name><name><surname>van den Bent</surname><given-names>M.J.</given-names></name><name><surname>Weller</surname><given-names>M.</given-names></name><name><surname>Fisher</surname><given-names>B.</given-names></name><name><surname>Taphoorn</surname><given-names>M.J.</given-names></name><name><surname>Belanger</surname><given-names>K.</given-names></name><name><surname>Brandes</surname><given-names>A.A.</given-names></name><name><surname>Marosi</surname><given-names>C.</given-names></name><name><surname>Bogdahn</surname><given-names>U.</given-names></name><etal></etal></person-group><article-title>Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma</article-title><source>N. Engl. J. Med.</source><year>2005</year><volume>352</volume><fpage>987</fpage><lpage>996</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa043330</pub-id><pub-id pub-id-type="pmid">15758009</pub-id></element-citation></ref><ref id="B2-ijms-18-00995"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab><name><surname>Brat</surname><given-names>D.J.</given-names></name><name><surname>Verhaak</surname><given-names>R.G.</given-names></name><name><surname>Aldape</surname><given-names>K.D.</given-names></name><name><surname>Yung</surname><given-names>W.K.</given-names></name><name><surname>Salama</surname><given-names>S.R.</given-names></name><name><surname>Cooper</surname><given-names>L.A.</given-names></name><name><surname>Rheinbay</surname><given-names>E.</given-names></name><name><surname>Miller</surname><given-names>C.R.</given-names></name><name><surname>Vitucci</surname><given-names>M.</given-names></name><etal></etal></person-group><article-title>Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>372</volume><fpage>2481</fpage><lpage>2498</lpage><pub-id pub-id-type="pmid">26061751</pub-id></element-citation></ref><ref id="B3-ijms-18-00995"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louis</surname><given-names>D.N.</given-names></name><name><surname>Ohgaki</surname><given-names>H.</given-names></name><name><surname>Wiestler</surname><given-names>O.D.</given-names></name><name><surname>Cavenee</surname><given-names>W.K.</given-names></name><name><surname>Burger</surname><given-names>P.C.</given-names></name><name><surname>Jouvet</surname><given-names>A.</given-names></name><name><surname>Scheithauer</surname><given-names>B.W.</given-names></name><name><surname>Kleihues</surname><given-names>P.</given-names></name></person-group><article-title>The 2007 WHO classification of tumours of the central nervous system</article-title><source>Acta Neuropathol.</source><year>2007</year><volume>114</volume><fpage>97</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1007/s00401-007-0243-4</pub-id><pub-id pub-id-type="pmid">17618441</pub-id></element-citation></ref><ref id="B4-ijms-18-00995"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agnihotri</surname><given-names>S.</given-names></name><name><surname>Burrell</surname><given-names>K.E.</given-names></name><name><surname>Wolf</surname><given-names>A.</given-names></name><name><surname>Jalali</surname><given-names>S.</given-names></name><name><surname>Hawkins</surname><given-names>C.</given-names></name><name><surname>Rutka</surname><given-names>J.T.</given-names></name><name><surname>Zadeh</surname><given-names>G.</given-names></name></person-group><article-title>Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies</article-title><source>Arch. Immunol. Ther. Exp.</source><year>2013</year><volume>61</volume><fpage>25</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1007/s00005-012-0203-0</pub-id><pub-id pub-id-type="pmid">23224339</pub-id></element-citation></ref><ref id="B5-ijms-18-00995"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wild-Bode</surname><given-names>C.</given-names></name><name><surname>Weller</surname><given-names>M.</given-names></name><name><surname>Rimner</surname><given-names>A.</given-names></name><name><surname>Dichgans</surname><given-names>J.</given-names></name><name><surname>Wick</surname><given-names>W.</given-names></name></person-group><article-title>Sublethal irradiation promotes migration and invasiveness of glioma cells: Implications for radiotherapy of human glioblastoma</article-title><source>Cancer Res.</source><year>2001</year><volume>61</volume><fpage>2744</fpage><lpage>2750</lpage><pub-id pub-id-type="pmid">11289157</pub-id></element-citation></ref><ref id="B6-ijms-18-00995"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangani</surname><given-names>D.</given-names></name><name><surname>Weller</surname><given-names>M.</given-names></name><name><surname>Seyed Sadr</surname><given-names>E.</given-names></name><name><surname>Willscher</surname><given-names>E.</given-names></name><name><surname>Seystahl</surname><given-names>K.</given-names></name><name><surname>Reifenberger</surname><given-names>G.</given-names></name><name><surname>Tabatabai</surname><given-names>G.</given-names></name><name><surname>Binder</surname><given-names>H.</given-names></name><name><surname>Schneider</surname><given-names>H.</given-names></name></person-group><article-title>Limited role for transforming growth factor-β pathway activation-mediated escape from VEGF inhibition in murine glioma models</article-title><source>Neuro Oncol.</source><year>2016</year><volume>18</volume><fpage>1610</fpage><lpage>1621</lpage><pub-id pub-id-type="doi">10.1093/neuonc/now112</pub-id><pub-id pub-id-type="pmid">27286797</pub-id></element-citation></ref><ref id="B7-ijms-18-00995"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fecci</surname><given-names>P.E.</given-names></name><name><surname>Mitchell</surname><given-names>D.A.</given-names></name><name><surname>Whitesides</surname><given-names>J.F.</given-names></name><name><surname>Xie</surname><given-names>W.</given-names></name><name><surname>Friedman</surname><given-names>A.H.</given-names></name><name><surname>Archer</surname><given-names>G.E.</given-names></name><name><surname>Herndon</surname><given-names>J.E.</given-names><suffix>2nd</suffix></name><name><surname>Bigner</surname><given-names>D.D.</given-names></name><name><surname>Dranoff</surname><given-names>G.</given-names></name><name><surname>Sampson</surname><given-names>J.H.</given-names></name></person-group><article-title>Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma</article-title><source>Cancer Res.</source><year>2006</year><volume>66</volume><fpage>3294</fpage><lpage>3302</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3773</pub-id><pub-id pub-id-type="pmid">16540683</pub-id></element-citation></ref><ref id="B8-ijms-18-00995"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frei</surname><given-names>K.</given-names></name><name><surname>Gramatzki</surname><given-names>D.</given-names></name><name><surname>Tritschler</surname><given-names>I.</given-names></name><name><surname>Schroeder</surname><given-names>J.J.</given-names></name><name><surname>Espinoza</surname><given-names>L.</given-names></name><name><surname>Rushing</surname><given-names>E.J.</given-names></name><name><surname>Weller</surname><given-names>M.</given-names></name></person-group><article-title>Transforming growth factor-β pathway activity in glioblastoma</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>5963</fpage><lpage>5977</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.3467</pub-id><pub-id pub-id-type="pmid">25849941</pub-id></element-citation></ref><ref id="B9-ijms-18-00995"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruna</surname><given-names>A.</given-names></name><name><surname>Darken</surname><given-names>R.S.</given-names></name><name><surname>Rojo</surname><given-names>F.</given-names></name><name><surname>Ocaña</surname><given-names>A.</given-names></name><name><surname>Peñuelas</surname><given-names>S.</given-names></name><name><surname>Arias</surname><given-names>A.</given-names></name><name><surname>Paris</surname><given-names>R.</given-names></name><name><surname>Tortosa</surname><given-names>A.</given-names></name><name><surname>Mora</surname><given-names>J.</given-names></name><name><surname>Baselga</surname><given-names>J.</given-names></name><etal></etal></person-group><article-title>High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the <italic>PDGF-B</italic> gene</article-title><source>Cancer Cell</source><year>2007</year><volume>11</volume><fpage>147</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.11.023</pub-id><pub-id pub-id-type="pmid">17292826</pub-id></element-citation></ref><ref id="B10-ijms-18-00995"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peñuelas</surname><given-names>S.</given-names></name><name><surname>Anido</surname><given-names>J.</given-names></name><name><surname>Prieto-Sánchez</surname><given-names>R.M.</given-names></name><name><surname>Folch</surname><given-names>G.</given-names></name><name><surname>Barba</surname><given-names>I.</given-names></name><name><surname>Cuartas</surname><given-names>I.</given-names></name><name><surname>García-Dorado</surname><given-names>D.</given-names></name><name><surname>Poca</surname><given-names>M.A.</given-names></name><name><surname>Sahuquillo</surname><given-names>J.</given-names></name><name><surname>Baselga</surname><given-names>J.</given-names></name><etal></etal></person-group><article-title>TGF-β increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma</article-title><source>Cancer Cell</source><year>2009</year><volume>15</volume><fpage>315</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2009.02.011</pub-id><pub-id pub-id-type="pmid">19345330</pub-id></element-citation></ref><ref id="B11-ijms-18-00995"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anido</surname><given-names>J.</given-names></name><name><surname>Sáez-Borderías</surname><given-names>A.</given-names></name><name><surname>Gonzàlez-Juncà</surname><given-names>A.</given-names></name><name><surname>Rodón</surname><given-names>L.</given-names></name><name><surname>Folch</surname><given-names>G.</given-names></name><name><surname>Carmona</surname><given-names>M.A.</given-names></name><name><surname>Prieto-Sánchez</surname><given-names>R.M.</given-names></name><name><surname>Barba</surname><given-names>I.</given-names></name><name><surname>Martínez-Sáez</surname><given-names>E.</given-names></name><name><surname>Prudkin</surname><given-names>L.</given-names></name><etal></etal></person-group><article-title>TGF-β receptor inhibitors target the CD44<sup>high</sup>/Id1<sup>high</sup> glioma-initiating cell population in human glioblastoma</article-title><source>Cancer Cell</source><year>2010</year><volume>18</volume><fpage>655</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2010.10.023</pub-id><pub-id pub-id-type="pmid">21156287</pub-id></element-citation></ref><ref id="B12-ijms-18-00995"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herbertz</surname><given-names>S.</given-names></name><name><surname>Sawyer</surname><given-names>J.S.</given-names></name><name><surname>Stauber</surname><given-names>A.J.</given-names></name><name><surname>Gueorguieva</surname><given-names>I.</given-names></name><name><surname>Driscoll</surname><given-names>K.E.</given-names></name><name><surname>Estrem</surname><given-names>S.T.</given-names></name><name><surname>Cleverly</surname><given-names>A.L.</given-names></name><name><surname>Desaiah</surname><given-names>D.</given-names></name><name><surname>Guba</surname><given-names>S.C.</given-names></name><name><surname>Benhadji</surname><given-names>K.A.</given-names></name><etal></etal></person-group><article-title>Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-β signaling pathway</article-title><source>Drug Des. Dev. Ther.</source><year>2015</year><volume>10</volume><fpage>4479</fpage><lpage>4499</lpage></element-citation></ref><ref id="B13-ijms-18-00995"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodon</surname><given-names>J.</given-names></name><name><surname>Carducci</surname><given-names>M.A.</given-names></name><name><surname>Sepulveda-Sánchez</surname><given-names>J.M.</given-names></name><name><surname>Azaro</surname><given-names>A.</given-names></name><name><surname>Calvo</surname><given-names>E.</given-names></name><name><surname>Seoane</surname><given-names>J.</given-names></name><name><surname>Braña</surname><given-names>I.</given-names></name><name><surname>Sicart</surname><given-names>E.</given-names></name><name><surname>Gueorguieva</surname><given-names>I.</given-names></name><name><surname>Cleverly</surname><given-names>A.L.</given-names></name><etal></etal></person-group><article-title>First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma</article-title><source>Clin. Cancer Res.</source><year>2015</year><volume>21</volume><fpage>553</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-1380</pub-id><pub-id pub-id-type="pmid">25424852</pub-id></element-citation></ref><ref id="B14-ijms-18-00995"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sepulveda-Sanchez</surname><given-names>J.</given-names></name><name><surname>Ramos</surname><given-names>A.</given-names></name><name><surname>Hilario</surname><given-names>A.</given-names></name><name><surname>DE Velasco</surname><given-names>G.</given-names></name><name><surname>Castellano</surname><given-names>D.</given-names></name><name><surname>Garcia de la Torre</surname><given-names>M.</given-names></name><name><surname>Rodon</surname><given-names>J.</given-names></name><name><surname>Lahn</surname><given-names>M.F.</given-names></name></person-group><article-title>Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate</article-title><source>Oncol. Lett.</source><year>2015</year><volume>9</volume><fpage>2442</fpage><lpage>2448</lpage><pub-id pub-id-type="pmid">26137087</pub-id></element-citation></ref><ref id="B15-ijms-18-00995"><label>15.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>S.</given-names></name><name><surname>Sawyer</surname><given-names>S.</given-names></name><name><surname>Yan</surname><given-names>L.</given-names></name><name><surname>Foreman</surname><given-names>R.</given-names></name><name><surname>Weir</surname><given-names>S.</given-names></name><name><surname>Lahn</surname><given-names>M.</given-names></name><name><surname>Yingling</surname><given-names>J.</given-names></name><name><surname>Graff</surname><given-names>J.R.</given-names></name></person-group><article-title>Abstract C201: The combination of the small molecule TGFβR1 inhibitor, LY2157299 monohydrate, with CCNU substantially blocks SMAD phosphorylation and significantly suppresses human glioblastoma xenograft growth</article-title><source>Proceedings of the 2011 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics</source><conf-loc>San Francisco, CA, USA</conf-loc><conf-date>12–16 November 2011</conf-date></element-citation></ref><ref id="B16-ijms-18-00995"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandes</surname><given-names>A.A.</given-names></name><name><surname>Carpentier</surname><given-names>A.F.</given-names></name><name><surname>Kesari</surname><given-names>S.</given-names></name><name><surname>Sepulveda-Sanchez</surname><given-names>J.M.</given-names></name><name><surname>Wheeler</surname><given-names>H.R.</given-names></name><name><surname>Chinot</surname><given-names>O.</given-names></name><name><surname>Cher</surname><given-names>L.</given-names></name><name><surname>Steinbach</surname><given-names>J.P.</given-names></name><name><surname>Capper</surname><given-names>D.</given-names></name><name><surname>Specenier</surname><given-names>P.</given-names></name><etal></etal></person-group><article-title>A phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma</article-title><source>Neuro Oncol.</source><year>2016</year><volume>18</volume><fpage>1146</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1093/neuonc/now009</pub-id><pub-id pub-id-type="pmid">26902851</pub-id></element-citation></ref><ref id="B17-ijms-18-00995"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab></person-group><article-title>Comprehensive genomic characterization defines human glioblastoma genes and core pathways</article-title><source>Nature</source><year>2008</year><volume>455</volume><fpage>1061</fpage><lpage>1068</lpage><pub-id pub-id-type="pmid">18772890</pub-id></element-citation></ref><ref id="B18-ijms-18-00995"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preusser</surname><given-names>M.</given-names></name><name><surname>Capper</surname><given-names>D.</given-names></name><name><surname>Hartmann</surname><given-names>C.</given-names></name></person-group><article-title>Euro-CNS Research Committee. IDH testing in diagnostic neuropathology: Review and practical guideline article invited by the Euro-CNS research committee</article-title><source>Clin. Neuropathol.</source><year>2011</year><volume>30</volume><fpage>217</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.5414/NP300422</pub-id><pub-id pub-id-type="pmid">21955925</pub-id></element-citation></ref><ref id="B19-ijms-18-00995"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wick</surname><given-names>W.</given-names></name><name><surname>Weller</surname><given-names>M.</given-names></name><name><surname>van den Bent</surname><given-names>M.</given-names></name><name><surname>Sanson</surname><given-names>M.</given-names></name><name><surname>Weiler</surname><given-names>M.</given-names></name><name><surname>von Deimling</surname><given-names>A.</given-names></name><name><surname>Plass</surname><given-names>C.</given-names></name><name><surname>Hegi</surname><given-names>M.</given-names></name><name><surname>Platten</surname><given-names>M.</given-names></name><name><surname>Reifenberger</surname><given-names>G.</given-names></name></person-group><article-title>MGMT testing—The challenges for biomarker-based glioma treatment</article-title><source>Nat. Rev. Neurol.</source><year>2014</year><volume>10</volume><fpage>372</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2014.100</pub-id><pub-id pub-id-type="pmid">24912512</pub-id></element-citation></ref><ref id="B20-ijms-18-00995"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galon</surname><given-names>J.</given-names></name><name><surname>Costes</surname><given-names>A.</given-names></name><name><surname>Sanchez-Cabo</surname><given-names>F.</given-names></name><name><surname>Kirilovsky</surname><given-names>A.</given-names></name><name><surname>Mlecnik</surname><given-names>B.</given-names></name><name><surname>Lagorce-Pagès</surname><given-names>C.</given-names></name><name><surname>Tosolini</surname><given-names>M.</given-names></name><name><surname>Camus</surname><given-names>M.</given-names></name><name><surname>Berger</surname><given-names>A.</given-names></name><name><surname>Wind</surname><given-names>P.</given-names></name><etal></etal></person-group><article-title>Type, density, and location of immune cells within human colorectal tumors predict clinical outcome</article-title><source>Science</source><year>2006</year><volume>313</volume><fpage>1960</fpage><lpage>1964</lpage><pub-id pub-id-type="doi">10.1126/science.1129139</pub-id><pub-id pub-id-type="pmid">17008531</pub-id></element-citation></ref><ref id="B21-ijms-18-00995"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gooden</surname><given-names>M.J.</given-names></name><name><surname>de Bock</surname><given-names>G.H.</given-names></name><name><surname>Leffers</surname><given-names>N.</given-names></name><name><surname>Daemen</surname><given-names>T.</given-names></name><name><surname>Nijman</surname><given-names>H.W.</given-names></name></person-group><article-title>The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis</article-title><source>Br. J. Cancer</source><year>2011</year><volume>105</volume><fpage>93</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/bjc.2011.189</pub-id><pub-id pub-id-type="pmid">21629244</pub-id></element-citation></ref><ref id="B22-ijms-18-00995"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>G.P.</given-names></name><name><surname>Dunn</surname><given-names>I.F.</given-names></name><name><surname>Curry</surname><given-names>W.T.</given-names></name></person-group><article-title>Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma</article-title><source>Cancer Immun.</source><year>2007</year><volume>7</volume><fpage>12</fpage><pub-id pub-id-type="pmid">17691714</pub-id></element-citation></ref><ref id="B23-ijms-18-00995"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kmiecik</surname><given-names>J.</given-names></name><name><surname>Poli</surname><given-names>A.</given-names></name><name><surname>Brons</surname><given-names>N.H.</given-names></name><name><surname>Waha</surname><given-names>A.</given-names></name><name><surname>Eide</surname><given-names>G.E.</given-names></name><name><surname>Enger</surname><given-names>P.</given-names></name><name><surname>Zimmer</surname><given-names>J.</given-names></name><name><surname>Chekenya</surname><given-names>M.</given-names></name></person-group><article-title>Elevated CD3<sup>+</sup> and CD8<sup>+</sup> tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level</article-title><source>J. Neuroimmunol.</source><year>2013</year><volume>264</volume><fpage>71</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2013.08.013</pub-id><pub-id pub-id-type="pmid">24045166</pub-id></element-citation></ref><ref id="B24-ijms-18-00995"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berghoff</surname><given-names>A.S.</given-names></name><name><surname>Kiesel</surname><given-names>B.</given-names></name><name><surname>Widhalm</surname><given-names>G.</given-names></name><name><surname>Rajky</surname><given-names>O.</given-names></name><name><surname>Ricken</surname><given-names>G.</given-names></name><name><surname>Wöhrer</surname><given-names>A.</given-names></name><name><surname>Dieckmann</surname><given-names>K.</given-names></name><name><surname>Filipits</surname><given-names>M.</given-names></name><name><surname>Brandstetter</surname><given-names>A.</given-names></name><name><surname>Weller</surname><given-names>M.</given-names></name><etal></etal></person-group><article-title>Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma</article-title><source>Neuro Oncol.</source><year>2015</year><volume>17</volume><fpage>1064</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nou307</pub-id><pub-id pub-id-type="pmid">25355681</pub-id></element-citation></ref><ref id="B25-ijms-18-00995"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Döring</surname><given-names>C.</given-names></name><name><surname>Hansmann</surname><given-names>M.L.</given-names></name><name><surname>Agostinelli</surname><given-names>C.</given-names></name><name><surname>Piccaluga</surname><given-names>P.P.</given-names></name><name><surname>Facchetti</surname><given-names>F.</given-names></name><name><surname>Pileri</surname><given-names>S.</given-names></name><name><surname>Küppers</surname><given-names>R.</given-names></name><name><surname>Newrzela</surname><given-names>S.</given-names></name><name><surname>Hartmann</surname><given-names>S.</given-names></name></person-group><article-title>A novel immunohistochemical classifier to distinguish Hodgkin lymphoma from ALK anaplastic large cell lymphoma</article-title><source>Mod. Pathol.</source><year>2014</year><volume>27</volume><fpage>1345</fpage><lpage>1354</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2014.44</pub-id><pub-id pub-id-type="pmid">24633193</pub-id></element-citation></ref><ref id="B26-ijms-18-00995"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wainwright</surname><given-names>D.A.</given-names></name><name><surname>Dey</surname><given-names>M.</given-names></name><name><surname>Chang</surname><given-names>A.</given-names></name><name><surname>Lesniak</surname><given-names>M.S.</given-names></name></person-group><article-title>Targeting tregs in malignant brain cancer: Overcoming IDO</article-title><source>Front. Immunol.</source><year>2013</year><volume>4</volume><fpage>116</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2013.00116</pub-id><pub-id pub-id-type="pmid">23720663</pub-id></element-citation></ref><ref id="B27-ijms-18-00995"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>J.K.</given-names></name><name><surname>Lieu</surname><given-names>A.S.</given-names></name><name><surname>Su</surname><given-names>Y.F.</given-names></name><name><surname>Cheng</surname><given-names>C.Y.</given-names></name><name><surname>Tsai</surname><given-names>T.H.</given-names></name><name><surname>Lin</surname><given-names>C.L.</given-names></name><name><surname>Lee</surname><given-names>K.S.</given-names></name><name><surname>Hwang</surname><given-names>S.L.</given-names></name><name><surname>Kwan</surname><given-names>A.L.</given-names></name><name><surname>Wang</surname><given-names>C.J.</given-names></name><etal></etal></person-group><article-title>Plasma levels of transforming growth factor-β1 before and after removal of low- and high-grade astrocytomas</article-title><source>Cytokine</source><year>2013</year><volume>61</volume><fpage>413</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2012.11.011</pub-id><pub-id pub-id-type="pmid">23260996</pub-id></element-citation></ref><ref id="B28-ijms-18-00995"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>F.</given-names></name><name><surname>Busby</surname><given-names>E.</given-names></name><name><surname>Marques</surname><given-names>M.B.</given-names></name><name><surname>Reynolds</surname><given-names>R.E.</given-names></name><name><surname>Carey</surname><given-names>D.E.</given-names></name></person-group><article-title>Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: Preliminary results</article-title><source>Lung Cancer</source><year>2003</year><volume>42</volume><fpage>237</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1016/S0169-5002(03)00354-4</pub-id><pub-id pub-id-type="pmid">14568692</pub-id></element-citation></ref><ref id="B29-ijms-18-00995"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>M.</given-names></name><name><surname>Bracci</surname><given-names>P.M.</given-names></name><name><surname>McCoy</surname><given-names>L.S.</given-names></name><name><surname>Hsuang</surname><given-names>G.</given-names></name><name><surname>Wiemels</surname><given-names>J.L.</given-names></name><name><surname>Rice</surname><given-names>T.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Kelsey</surname><given-names>K.T.</given-names></name><name><surname>Wrensch</surname><given-names>M.R.</given-names></name><name><surname>Wiencke</surname><given-names>J.K.</given-names></name></person-group><article-title>Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time</article-title><source>Int. J. Cancer</source><year>2015</year><volume>137</volume><fpage>826</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1002/ijc.29441</pub-id><pub-id pub-id-type="pmid">25604093</pub-id></element-citation></ref><ref id="B30-ijms-18-00995"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barth</surname><given-names>S.D.</given-names></name><name><surname>Schulze</surname><given-names>J.J.</given-names></name><name><surname>Kühn</surname><given-names>T.</given-names></name><name><surname>Raschke</surname><given-names>E.</given-names></name><name><surname>Hüsing</surname><given-names>A.</given-names></name><name><surname>Johnson</surname><given-names>T.</given-names></name><name><surname>Kaaks</surname><given-names>R.</given-names></name><name><surname>Olek</surname><given-names>S.</given-names></name></person-group><article-title>Treg-mediated immune tolerance and the risk of solid cancers: Findings from EPIC-Heidelberg</article-title><source>J. Natl. Cancer Inst.</source><year>2015</year><volume>107</volume><pub-id pub-id-type="doi">10.1093/jnci/djv224</pub-id><pub-id pub-id-type="pmid">26298011</pub-id></element-citation></ref><ref id="B31-ijms-18-00995"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baron</surname><given-names>U.</given-names></name><name><surname>Floess</surname><given-names>S.</given-names></name><name><surname>Wieczorek</surname><given-names>G.</given-names></name><name><surname>Baumann</surname><given-names>K.</given-names></name><name><surname>Grützkau</surname><given-names>A.</given-names></name><name><surname>Dong</surname><given-names>J.</given-names></name><name><surname>Thiel</surname><given-names>A.</given-names></name><name><surname>Boeld</surname><given-names>T.J.</given-names></name><name><surname>Hoffmann</surname><given-names>P.</given-names></name><name><surname>Edinger</surname><given-names>M.</given-names></name><etal></etal></person-group><article-title>DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3<sup>+</sup> conventional T cells</article-title><source>Eur. J. Immunol.</source><year>2007</year><volume>37</volume><fpage>2378</fpage><lpage>2389</lpage><pub-id pub-id-type="doi">10.1002/eji.200737594</pub-id><pub-id pub-id-type="pmid">17694575</pub-id></element-citation></ref><ref id="B32-ijms-18-00995"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frampton</surname><given-names>G.M.</given-names></name><name><surname>Fichtenholtz</surname><given-names>A.</given-names></name><name><surname>Otto</surname><given-names>G.A.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Downing</surname><given-names>S.R.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Schnall-Levin</surname><given-names>M.</given-names></name><name><surname>White</surname><given-names>J.</given-names></name><name><surname>Sanford</surname><given-names>E.M.</given-names></name><name><surname>An</surname><given-names>P.</given-names></name><etal></etal></person-group><article-title>Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing</article-title><source>Nat. Biotechnol.</source><year>2013</year><volume>31</volume><fpage>1023</fpage><lpage>1031</lpage><pub-id pub-id-type="doi">10.1038/nbt.2696</pub-id><pub-id pub-id-type="pmid">24142049</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="ijms-18-00995-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Forest plot showing the univariate impact of various tissue markers on overall survival (OS). HR &lt; 1 indicates improved OS for the left hand side of the comparison compared to the right hand side. For example, patients with a pSMAD2 Nucleus H score &gt;100 had numerically longer OS than patients with a pSMAD2 Nucleus H score ≤100. No comparisons reached statistical significance.</p></caption><graphic xlink:href="ijms-18-00995-g001"></graphic></fig><fig id="ijms-18-00995-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>(<bold>A</bold>–<bold>D</bold>): Kaplan–Meier plots showing the impact of tissue CD3 and pSMAD2 on OS. No comparisons reached statistical significance. Respective log rank <italic>p</italic>-values are: (<bold>A</bold>) 0.2169; (<bold>B</bold>) 0.9360; (<bold>C</bold>) 0.2076; and (<bold>D</bold>) 0.4499.</p></caption><graphic xlink:href="ijms-18-00995-g002a"></graphic><graphic xlink:href="ijms-18-00995-g002b"></graphic></fig><fig id="ijms-18-00995-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Line plot of least-square (LS) mean fold change in laboratory markers over time by treatment. Numbers annotated on the plot represent the number of patients with evaluable data for each cycle. Results need to be interpreted with caution since sample sizes are small at later cycles as patients discontinued treatment. The following parameters had an overall treatment effect of <italic>p</italic> &lt; 0.05: CD4<sup>+</sup>, CD4<sup>+</sup>/CD8<sup>+</sup> ratio, lymphocytes, lactate dehydrogenase (LDH), eosinophils. Additional parameters that were considered in exploratory analyses included serum C-reactive protein (CRP), blood CD3<sup>+</sup>, FOXP3, CD8<sup>+</sup>, CD4<sup>+</sup>CD25<sup>+</sup>CD127<sup>−</sup>/LOFOXP3<sup>+</sup>, monocytes, neutrophils, neutrophil/lymphocyte ratio, and TGF-β1, but no consistent significant differences among treatment arms were observed over time; overall treatment <italic>p</italic> &gt; 0.05. Comparison of galunisertib monotherapy versus placebo plus lomustine, * <italic>p</italic> &lt; 0.05, ** <italic>p</italic> &lt; 0.01, *** <italic>p</italic> &lt; 0.001; Comparison of galunisertib monotherapy versus galunisertib plus lomustine, + <italic>p</italic> &lt; 0.05, ++ <italic>p</italic> &lt; 0.01; +++ <italic>p</italic> &lt; 0.001; Comparison of galunisertib plus lomustine versus placebo plus lomustine, ^ <italic>p</italic> &lt; 0.05, ^^ <italic>p</italic> &lt; 0.01, ^^^ <italic>p</italic> &lt; 0.001.</p></caption><graphic xlink:href="ijms-18-00995-g003a"></graphic><graphic xlink:href="ijms-18-00995-g003b"></graphic></fig><table-wrap id="ijms-18-00995-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-18-00995-t001_Table 1</object-id><label>Table 1</label><caption><p>Summary of histopathological evaluation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Evaluation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Result</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">All Patients <italic>n</italic> (%) <sup>a</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Patients with Glioblastoma, Gliosarcoma or Giant Cell Glioblastoma, and IDH1 R132H Negative <italic>n</italic> (%) <sup>a</sup></th></tr></thead><tbody><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Diagnosis</td><td align="center" valign="middle" rowspan="1" colspan="1">Glioblastoma</td><td align="center" valign="middle" rowspan="1" colspan="1">116 (92)</td><td align="center" valign="middle" rowspan="1" colspan="1">103 (96)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Glioma, astrocytoma</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Glioma, gliosarcoma</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (2)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Glioma, pleomorphic xanthoastrocytoma</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Protoplasmic astrocytoma</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Oligoastrocytoma</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Giant cell glioblastoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1)</td></tr><tr><td rowspan="13" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Assessment of differentiation</td><td align="center" valign="middle" rowspan="1" colspan="1">Perinuclear halos</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (9)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (7)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fibrillary astrocytoma-like foci</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (7)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Small cell astrocytoma-like foci</td><td align="center" valign="middle" rowspan="1" colspan="1">27 (21)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (20)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Polar spongioblastic foci</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Protoplasmic astrocytoma-like foci</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Minigemistocytes</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (4)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Classic gemistocytes</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (13)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (11)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Giant cells</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (13)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (14)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PNET-like</td><td align="center" valign="middle" rowspan="1" colspan="1">13 (10)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (10)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sarcoma-like</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (6)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (7)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Microcysts</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (19)</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (17)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mucoid degeneration</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (9)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (8)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Calcifications</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2)</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Vessel structure</td><td align="center" valign="middle" rowspan="1" colspan="1">Abnormal number of vessels</td><td align="center" valign="middle" rowspan="1" colspan="1">117 (93)</td><td align="center" valign="middle" rowspan="1" colspan="1">101 (94)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Any endothelial hypertrophy</td><td align="center" valign="middle" rowspan="1" colspan="1">124 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">107 (100)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Glomeruloid blood vessel</td><td align="center" valign="middle" rowspan="1" colspan="1">69 (56)</td><td align="center" valign="middle" rowspan="1" colspan="1">62 (58)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Multi-layering blood vessel</td><td align="center" valign="middle" rowspan="1" colspan="1">116 (94)</td><td align="center" valign="middle" rowspan="1" colspan="1">103 (96)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Vascular abnormalities</td><td align="center" valign="middle" rowspan="1" colspan="1">124 (98)</td><td align="center" valign="middle" rowspan="1" colspan="1">107 (100)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vessel thrombosis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">87 (69)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">80 (75)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Cellular density</td><td align="center" valign="middle" rowspan="1" colspan="1">Low (like diffuse astrocytoma)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (4)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (5)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Medium (like classical glioblastoma)</td><td align="center" valign="middle" rowspan="1" colspan="1">100 (79)</td><td align="center" valign="middle" rowspan="1" colspan="1">86 (80)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High (like PNET)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">21 (17)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (15)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Tumor necrosis</td><td align="center" valign="middle" rowspan="1" colspan="1">Yes, with pseudopalisading</td><td align="center" valign="middle" rowspan="1" colspan="1">36 (29)</td><td align="center" valign="middle" rowspan="1" colspan="1">34 (32)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes, without pseudopalisading</td><td align="center" valign="middle" rowspan="1" colspan="1">72 (57)</td><td align="center" valign="middle" rowspan="1" colspan="1">64 (60)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (14)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (8)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Mitotic scoring</td><td align="center" valign="middle" rowspan="1" colspan="1">≤5 Mitoses (per 10 Highpower fields)</td><td align="center" valign="middle" rowspan="1" colspan="1">31 (25)</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (23)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6–20 Mitoses (per 10 Highpower fields)</td><td align="center" valign="middle" rowspan="1" colspan="1">66 (53)</td><td align="center" valign="middle" rowspan="1" colspan="1">59 (56)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;20 Mitoses (per 10 Highpower fields)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28 (22)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 (22)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Nuclear abnormalities</td><td align="center" valign="middle" rowspan="1" colspan="1">Low (nuclear aspect as in normal glial cells)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (3)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Medium (abnormal nuclear shape)</td><td align="center" valign="middle" rowspan="1" colspan="1">92 (73)</td><td align="center" valign="middle" rowspan="1" colspan="1">78 (73)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High (bizarre nuclei)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 (24)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28 (26)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CD3 parenchymal lymphocytic infiltrate</td><td align="center" valign="middle" rowspan="1" colspan="1">≤1%</td><td align="center" valign="middle" rowspan="1" colspan="1">54 (47)</td><td align="center" valign="middle" rowspan="1" colspan="1">47 (45)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2–4%</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (36)</td><td align="center" valign="middle" rowspan="1" colspan="1">40 (38)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">≥5%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 (17)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (17)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CD3 perivascular lymphocytic infiltrate</td><td align="center" valign="middle" rowspan="1" colspan="1">None (≤4 perivascular positive cells per vessel)</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (21)</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (20)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Slight (≥1 vessel with ≥5 and &lt;30 positive perivascular cells)</td><td align="center" valign="middle" rowspan="1" colspan="1">43 (37)</td><td align="center" valign="middle" rowspan="1" colspan="1">38 (36)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prominent (≥1 vessel with ≥5 and ≥30 positive perivascular cells)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48 (42)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46 (44)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">IDH1 R132H</td><td align="center" valign="middle" rowspan="1" colspan="1">Positive</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (7)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Negative</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108 (93)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">107 (100)</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ki67</td><td align="center" valign="middle" rowspan="1" colspan="1">≤5%</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (6)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6–10%</td><td align="center" valign="middle" rowspan="1" colspan="1">25 (24)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (24)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">11–20%</td><td align="center" valign="middle" rowspan="1" colspan="1">43 (41)</td><td align="center" valign="middle" rowspan="1" colspan="1">37 (39)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;20%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32 (30)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 (31)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Glial fibrillary acid protein </td><td align="center" valign="middle" rowspan="1" colspan="1">Cytoplasm Total Detected (H score &gt; 0)</td><td align="center" valign="middle" rowspan="1" colspan="1">124 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">105 (100)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytoplasm H score Median (25th percentile, 75th percentile)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">140 (70, 210)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">150 (90 210)</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">pSMAD2</td><td align="center" valign="middle" rowspan="1" colspan="1">Cytoplasm Total Detected (H score &gt; 0)</td><td align="center" valign="middle" rowspan="1" colspan="1">22 (18)</td><td align="center" valign="middle" rowspan="1" colspan="1">18 (18)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Cytoplasm H score Median (25th percentile, 75th percentile)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0, 0)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0, 0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nuclei Total Detected (H score &gt; 0)</td><td align="center" valign="middle" rowspan="1" colspan="1">119 (100)</td><td align="center" valign="middle" rowspan="1" colspan="1">102 (100)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nuclei H score Median (25th percentile, 75th percentile)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 (70, 160)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">110 (75, 160)</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> The denominator for the percentage calculation is the number of randomized patients with a tumor sample for which an evaluable result was obtained. Percentages are rounded to the nearest integer.</p></fn></table-wrap-foot></table-wrap><table-wrap id="ijms-18-00995-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">ijms-18-00995-t002_Table 2</object-id><label>Table 2</label><caption><p>Summary of baseline tissue and plasma characteristics by isocitrate dehydrogenase 1 (IDH1) mutation status.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameter</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IDH1 Positive (<italic>n</italic> = 8)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IDH1 Negative (<italic>n</italic> = 108)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic>-Value</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Tissue CD3<sup>+</sup> Parenchymal infiltrate, <italic>n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">≤1%, 7 (88)</td><td align="center" valign="middle" rowspan="1" colspan="1">≤1%, 47 (44)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.026</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2–4%, 0</td><td align="center" valign="middle" rowspan="1" colspan="1">2–4%, 40 (38)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">≥5%, 1 (13)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">≥5%, 19 (18)</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Tissue CD3<sup>+</sup> Perivascular infiltrate, <italic>n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">None, 3 (38)</td><td align="center" valign="middle" rowspan="1" colspan="1">None, 21 (20)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.0267</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Slight, 5 (63)</td><td align="center" valign="middle" rowspan="1" colspan="1">Slight, 38 (36)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prominent, 0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prominent, 47 (44)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Blood FOXP3 (%), <italic>n</italic> Median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 8</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 101</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.0394</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.4 (0.3, 3.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.7 (0.1, 2.7)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Plasma MDC/CCL22 (pg/mL), <italic>n</italic> Median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 8</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 104</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.2533</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">491 (64, 879)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">208 (24, 1220)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Blood neutrophils (GI/L), <italic>n</italic> Median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 8</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 98</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.1505</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.50 (2.65, 11.23)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.53 (2.01, 16.81)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Blood neutrophil/lymphocyte ratio, <italic>n</italic>, Median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 8</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 98</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.0938</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.63 (1.52, 18.11)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.74 (0.81, 35.75)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Plasma TGF-β1 (pg/mL), <italic>n</italic> Median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 8</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 100</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.1027</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2984 (654, 19774)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2031 (25, 11325)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Blood CD4<sup>+</sup> (cells/uL), <italic>n</italic> Median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 8</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 96</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.1714</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">602 (108, 659)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">309 (30, 1208)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Blood CD3<sup>+</sup> (%), <italic>n</italic> Median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 8</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 101</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.3016</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.5 (3.1, 42.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.6 (2.6, 75.4)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Blood lymphocytes (GI/L), <italic>n</italic> Median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 8</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 98</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.2562</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.33 (0.57, 1.99)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.93 (0.22, 2.74)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Blood CD4<sup>+</sup>/CD8<sup>+</sup> Ratio, <italic>n</italic> Median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 8</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 96</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.368</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.75 (0.40, 2.58)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.27 (0.29, 6.31)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Tissue pSMAD2 cytoplasm H score, <italic>n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">H = 0, 6 (75)</td><td align="center" valign="middle" rowspan="1" colspan="1">H = 0, 85 (83)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.6334</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H &gt; 0, 2 (25)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H &gt; 0, 18 (18)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Blood eosinophils (GI/L), <italic>n</italic> Median (range)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 8</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>n</italic> = 98</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.7284</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.06 (0.00, 0.16)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.05 (0.00, 0.23)</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Tissue pSMAD2 nucleus H score, <italic>n</italic> (%)</td><td align="center" valign="middle" rowspan="1" colspan="1">H ≤ 100, 4 (50)</td><td align="center" valign="middle" rowspan="1" colspan="1">H ≤ 100, 50 (49)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">&gt;0.9999</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H &gt; 100, 4 (50)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H &gt; 100, 53 (52)</td></tr></tbody></table><table-wrap-foot><fn><p>Tissue samples are obtained up to five years prior to plasma/blood sampling; thus temporal changes in plasma/blood sampling may confound results. The median (range) is presented for continuous variables. <italic>p</italic>-values are calculated by analysis of variance using log transformed data for continuous measures and Fisher’s exact test for categorical measures.</p></fn></table-wrap-foot></table-wrap></floats-group></article>